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The aryl hydrocarbon receptor (AhR) is a PAS domain transcriptional factor also known as the 
“dioxin receptor” or “xenobiotic receptor.” My thesis work has uncovered an endobiotic role for 
AhR in hepatic steatosis and other metabolic functions. Activation of AhR induced spontaneous 
hepatic steatosis, which is characterized by the accumulation of triglycerides. The steatotic effect 
of AhR was likely due to the combined upregulation of fatty acid translocase CD36/FAT, 
suppression of fatty acid oxidation, inhibition of hepatic export of triglycerides, and an increase 
in the mobilization of peripheral fat. Promoter analysis established CD36 as a novel 
transcriptional target of AhR. Moreover, the steatotic effect of an AhR agonist was inhibited in 
mice deficient of CD36. Results from this study may help to establish AhR and its target fatty 
acid translocase CD36 as attractive targets for intervention in fatty liver disease.  
The liver X receptors (LXRs), both the  and  isoforms, are nuclear receptors identified as 
sterol sensors that modulate cholesterol and lipid metabolism and homeostasis. In the second part 
of my thesis research, I report a novel LXR-mediated mechanism of androgen deprivation. 
Genetic or pharmacological activation of the liver X receptor (LXR) in vivo lowered androgenic 
activity by inducing the hydroxysteroid sulfotransferase 2A1 (SULT2A1), an enzyme essential 
for the metabolic deactivation of androgens. Activation of LXR also inhibited the expression of 
steroid sulfatase (STS) in the prostate, which may have helped to prevent the local conversion of 
sulfonated androgens back to active metabolites. At the physiological level, activation of LXR in 
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mice inhibited androgen-dependent prostate regeneration in castrated mice. Treatment with LXR 
agonists inhibited androgen-dependent proliferation of prostate cancer cells in LXR- and 
SULT2A1-dependent manner. The ability of LXRs to regulate androgen metabolism makes them 
novel therapeutic targets for the treatment and prevention of hormone-dependent prostate cancer.   
Taken together, my work has revealed novel functions of AhR in lipid metabolism and 
LXR in androgen deprivation. It is hoped that understandings of the endobiotic functions of AhR 
and LXR may establish these two receptors as therapeutic targets for the management of 
metabolic disease in humans.   
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1.0  INTRODUCTION 
1.1 AN OVERVIEW OF AHR AND LXR AS XENOBIOTIC AND ENDOBIOTIC 
SENSORS 
 
The expression of many genes involved in xenobiotic and endobiotic metabolism is regulated by 
the aryl hydrocarbon receptor (AhR) and the orphan nuclear receptors, such as the liver X 
receptor (LXR). Both AhR and LXR are ligand-dependent transcription factors that sense 
endogenous or xenobiotic signals and subsequently regulate the expression of their target genes. 
The regulation of target genes is achieved by binding of the receptors to DNA responsive 
elements in enhancer or promoter regions of target genes. The regulation of target gene in turn 
will affect the homeostasis of numerous xenobiotics and endobiotics, such as bile acids, lipids, 
hormones, glucose, fat-soluble vitamins and mediators of the inflammatory process (Pascussi et 
al., 2008).  
AhR belongs to the basic helix-loop-helix (bHLH) PER-ARNT-SIM (PAS) family 
(Figure 1). The prototypical AhR ligand is an environmental contaminant 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), therefore it is also called „dioxin receptor‟ (Hoffman et al., 
1991). AhR binds structurally diverse xenobiotic chemicals, such as 3-methylcholanthrene (3-
MC) and endobiotic chemicals, such as indigo and 6-formylindolo[3,2b]carbazole (FICZ). Prior 
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to ligand binding, AhR is located in the cytoplasm, associating with HSP90, X-associated protein 
Figure 1 Functional domain of aryl hydrocarbon receptor (AhR) and AhR 
pathway (A) Schematic illustration of structural and functional organization of 
AhR. NLS, nuclear localization signal; NES, nuclear export  signal; HLH, helix-
loop-helix; Hsp90, heat shock protein 90; ARNT, AhR nuclear translocator; 
DNA, DNA binding domain; Ligand, ligand binding domain; PAS, PER-
ARNT-SIM; AIP, AhR interacting protein; TAD, transactivation domain; TI, 
transcription inhibitory domain (B) Model of AhR signaling. AhR normally 
resides in the cytoplasm, stably associated with two heat shock protein 90 
(Hsp90). AhR regulatory proteins, including p23 and XAP2 also stabilize AhR 
in cytoplasm. On activation by ligands results in AhR translocation into the 
nucleus where AhR is heterdimerized with AhR nuclear translocator (ARNT). 
The AhR-ARNT heterodimer regulates its target genes by binding to dioxin 
responsive element (DRE) present in the promoter region.    
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2 (XAP2, also known as ARA9 or AIP), and HSP90 co-chaperone p23 (Carlson and Perdew, 
2002). Binding of a ligand to AhR triggers nuclear translocation and allows heterodimerization 
with the AhR nuclear translocator (ARNT) (Reyes et al., 1992). AhR-ARNT heterodimers bind 
to dioxin responsive element (DRE) in the promoter region of target genes. The consensus DRE 
is TNGCGTG (Gu et al., 2000).  
The liver X receptors LXR and LXR are lipid-activated nuclear receptors that were 
first identified as cholesterol sensors. LXRs, like many other nuclear receptor superfamily 
members, consist of a N-terminal DNA-binding domain (DBD) and a C-terminal ligand-binding 
domain (LBD) (Figure 2). It is generally believed that in the absence of ligands, LXRs recruit 
complexes of corepressors, including NCoR, SMRT, RIP140, and SHP, that silence the 
transcription of target genes (Gronemeyer et al., 2004). Upon ligand binding, increased 
transcription is achieved by conformational changes of the receptors that lead to exchanges of 
corepressors with coactivators, such as the p160 family of coactivators (SRC-1, SRC-2/GRIP1, 
and SRC-3/ACTR/AIB1) (McKenna and O'Malley, 2002) and heterodimerization with retinoid 
Figure 2 Structural domain of liver X receptor (LXR) and LXR-mediated regulation 
of gene. (A) Domain structures of nuclear receptors. AF1 and 2, activation domain 1 
and 2; DBD, DNA binding domain; LBD, ligand binding domain (B) Liver X 
receptor (LXR) pathway. Within the nucleus, LXR/RXR heterodimers are bound to 
LXREs in the promoters of target genes and in complex with corepressors, such as 
SMRT and NCOR. Ligand binding recruits coactivators, leading to induction of 
target gene expression.  
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X receptors (RXRs). LXR-RXR heterodimers bind to DNA-responsive elements that contain 
direct repeats (DRs) of the consensus motifs AG(G/T)TC(A/C) separated by four base pair (DR-
4) (Chawla et al., 2001) or inverted repeats separated by no base pairs IR-0 (Uppal et al., 2007). 
LXR agonists include the endogenous cholesterol metabolites, such as 24(S),25-
epoxycholesterol, 24(S)-hydroxycholesterol, 22(R)-hydroxycholesterol (Repa and Mangelsdorf, 
2002), as well as synthetic agonists, such as TO0901317 (TO1317) (Schultz et al., 2000) and 
GW3965 (Collins et al., 2002).  
My thesis work has established AhR as a key modulator of lipid metabolism (Chapter II) 
and LXRs as a regulator of androgen metabolism, which links to prostate cancer (Chapter III).  
1.2 GENERAL SIGNALING AND FUNCTION OF AHR AND LXR 
1.2.1 AhR 
Vertebrates have developed a general strategy to protect themselves from adverse chemical 
environments by up-regulating batteries of xenobiotic metabolizing enzymes (XMEs), thus 
decreasing the biological half-life of the insulting chemicals. XMEs include phase I, phase II 
metabolizing enzymes and phase III transporters. They are present in abundance either at the 
basal or inducible levels in response to xenobiotics exposures. It has long been observed that a 
number of XMEs are regulated by ligand-dependent transcription factors, including the PAS 
domain transcription factor AhR, and nuclear hormone receptors, constitutive androstane 
receptor (CAR), and pregnane X receptor (PXR). AhR can induce the expression of the 
microsomal cytochrome P450-dependent monooxygenase 1 (CYP1) genes in response to 
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halogenated aromatic hydrocarbons (HAHs) and polycyclic aromatic hydrocarbons (PAHs). 
Phase II glutathione S-transferases (GSTs) and UDP-glucuronosyltransferases (UGTs) have also 
been shown to be regulated by AhR. Most of these enzymes appear to have metabolic activity 
toward PAHs, such as benzo[a]pyrene and 3-methylcholantherene, and are believed to decrease 
their biological half-life. Therefore, AhR function is believed to be an adaptive response to the 
cellular environmental and a sensor to xenobiotic signals. However, it has become clear that in 
addition to its role in regulating drug metabolizing enzymes, AhR is also a primary mediator of 
HAHs and PAHs-induced toxicity. Sustained activation of AhR by HAH and PAH mediates a 
pleiotropic effect of species- and tissue-dependent toxicities, including cancer, 
immunosuppression, liver damage, and birth defects. The HAHs and PAHs-mediated toxic 
effects appear to be AhR-dependent since the responses to benzo[a]pyrene or dioxin were 
abrogated by the genetic ablation of AhR (Fernandez-Salguero et al., 1995; Schmidt et al., 1996; 
Shimizu et al., 2000). Although the mechanisms underlying these toxic effects are largely 
unsolved, it has been hypothesized that AhR-mediated induction of CYP1A and 1B1 contributes 
to the metabolic activation of carcinogens. These enzymes catalyze the epoxidation of PAHs, 
resulting in the generation of highly reactive intermediate that are capable of binding covalently 
to specific residues of DNA. The formation of DNA adduct causes mutation, birth defects and 
toxicity followed ultimately by carcinogenesis. In contrast to PAHs that undergo metabolic 
conversion into DNA-reactive intermediates, dioxin and other HAHs are non-genotoxic 
compounds that fail to form a DNA adduct but show carcinogenic effects. A link between AhR 
and dioxin toxicity has been established with the use of AhR
-/-
 mice, however, the mechanisms 
behind a wide range of toxic effects by dioxin remain unresolved.   
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Although AhR has been identified as a „xenobiotic receptor‟, emerging evidence has 
pointed to an equally important role of AhR as an „endobiotic receptor‟. Subsequent studies, 
mainly through the characterization of AhR
-/-
 mice, suggest that AhR also has endobiotic 
functions by affecting physiology and tissue development. For example, AhR
-/-
 mice had smaller 
livers (Fernandez-Salguero et al., 1995; Schmidt et al., 1996) and vascular abnormalities (Lahvis 
et al., 2000). The most abnormal vascular pattern reported in AhR
-/-
 mice is a patent Ductus 
Venosus (DV) (Lahvis et al., 2000) which is a porto-systemic shunt allowing portal blood to 
reach the systemic circulation without first passing through the liver. The endobiotic function of 
AhR has also been supported by recent identification of endogenous AhR agonists, such as 
indoles (Adachi et al., 2001), arachidonic acid metabolites (Seidel et al., 2001), modified LDL 
(McMillan and Bradfield, 2007), and leukotrine A4 metabolites (Chiaro et al., 2008). Therefore, 
the AhR functions can be classified into: 1) adaptive response which results in the detoxification 
of toxicants by enhanced metabolism, 2) toxic response through the induction of genes involved 
in metabolic activation of toxicants, and 3) developmental effects which are likely resulted from 
activation of the receptors by endogenous ligands. 
1.2.2 LXR 
LXRs, both the  and  isoforms, were known as sterol sensors that regulate cholesterol and 
lipid metabolism and homeostasis (Willy et al., 1995). LXR is highly expressed in the liver, but 
its expression is also found in adipose tissues, intestine, macrophages, lung and kidney. LXR is 
expressed ubiquitously (Zelcer and Tontonoz, 2006). LXR and LXR are highly conserved, 
sharing 76% and 78% sequence homology in their DNA binding domain (DBD) and ligand 
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binding domain (LBD), respectively. LXR and LXR share many of the DNA response 
elements as well as endogenous and exogenous ligands. LXRs possess diverse functions, ranging 
from cholesterol efflux to lipogenesis and anti-inflammation. For this reasons, LXRs have been 
explored as a therapeutic target for atherosclerosis, diabetics, and Alzheimer‟s disease in animal 
models. In rodents, activation of LXR increases cholesterol catabolism. LXRdeficient mice 
exhibited a marked increase in cholesteryl ester accumulation and LDL cholesterol levels in their 
livers but a decrease in HDL cholesterol levels when challenged with a high-cholesterol diet 
(Peet et al., 1998). In contrast, LXR deficient mice do not display an obvious phenotype in the 
response to high-cholesterol challenge (Alberti et al., 2001), implying that LXRplays a more 
prominent role in hepatic cholesterol metabolism. The first target gene in cholesterol metabolism 
induced by LXR was identified as cholesterol 7-hydroxylase (Cyp7a1), the rate limiting 
enzyme in the synthetic pathway that catalyzes for the formation of bile acid from cholesterol 
(Peet et al., 1998). LXRs were later found to increase the expression of the ATP-binding cassette 
(ABC) superfamily of transporters, including ABCA1, ABCG5, ABCG8 and ABCG1, resulting 
in cholesterol secretion into the bile and limiting dietary cholesterol absorption (Repa et al., 
2000b). Treatment with LXR ligands, such as TO1317 and GW3965, lowers cholesterol level 
and inhibits the development of atherosclerosis in mouse models (Barish and Evans, 2004; Repa 
and Mangelsdorf, 2002).  
Despite their promise as anti-atherosclerotic targets, LXRs have also been linked to 
hepatic lipogenesis (Repa et al., 2000a; Schultz et al., 2000; Yoshikawa et al., 2001). Treatment 
of mice with LXR agonists elevates triglyceride levels in the liver as well as in the plasma (Repa 
et al., 2000a; Schultz et al., 2000).  LXR activation increases plasma triglyceride levels through 
the transcriptional activation of SREBP-1c, a transcriptional factor known to regulate the 
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expression of a battery of lipogenic enzymes, including SCD-1, ACC-1 and FAS. Accumulating 
evidence suggests that LXRs may also promote steatosis in a SREBP-independent manner. For 
example, FAS (Joseph et al., 2002), ACC-1 (Talukdar and Hillgartner, 2006) and SCD-1 (Chu et 
al., 2006) can be directly regulated by LXR, instead of being mediated by SREBP activation. 
LXRs positively regulate several transcription factors involved in lipogenesis, including 
PPARSeo et al  and carbohydrate response element-binding protein (ChREBP) (Cha 
and Repa, 2007), a glucose-sensitive transcription factor and a regulator of conversion to lipids 
from excess carbohydrates. Activation of LXR has also been reported to induce enzymes in 
lipoprotein remodeling, such as lipoprotein lipase (LPL) (Zhang et al., 2001), a rate-limiting 
enzyme for catabolism of triglyceride from VLDL and chylomicrons.  
In macrophages, LXRs play an important role in innate immunity and inflammatory 
signaling (Glass and Ogawa, 2006; Zelcer and Tontonoz, 2006). LXR agonists enhance 
macrophage survival during bacterial infection. Mice lacking LXRs were highly susceptible to 
the intracellular pathogen Listeria monocytogenes infection and this phenotype was recapitulated 
by transplantation of bone marrow from LXR-/- mice into WT mice, indicating LXRs are 
required for innate immune response (Joseph et al., 2004). In addition, activation of LXRs 
inhibits the lipopolysaccharide (LPS) induction of a number of proinflammatory genes such as 
inducible nitric oxide synthase (iNOS), cytokines such as interleukin-1 (IL1), and chemokines 
such as monocyte chemoattractant protein-1 (MCP-1) (Joseph et al., 2003). These observations 
have established LXRs as key modulators of both lipid metabolism and inflammatory signaling. 
More recently, we showed that LXR can alleviate cholestasis by enhancing bile acid 
detoxification (Uppal et al., 2007), and promote estrogen deprivation by activating the estrogen 
sulfotransferase (EST) (Gong et al., 2007).    
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2.0  AN ENDOBIOTIC ROLE OF AHR IN HEPATIC STEATOSIS 
2.1 BACKGROUND 
Hepatic steatosis, or fatty liver, is a common medical problem strongly associated with metabolic 
syndrome, which is characterized by insulin resistance and a high risk for cardiovascular disease 
(Kotronen and Yki-Jarvinen, 2008; Postic and Girard, 2008). The liver plays a central role in 
fatty acid and triglyceride metabolism (Lee et al., 2008b; Shi and Burn, 2004) (see Figure 3). In 
the fed state, the liver ensures an adequate supply of fuel substrate from glucose, which is 
required for de novo fatty acid synthesis. The hepatic de novo fatty acid synthesis is controlled 
by the dedicated lipogenic transcriptional factor sterol regulatory element binding protein 1c 
(SREBP-1c) that regulates a battery of lipogenic enzymes, including fatty acid synthase (FAS), 
stearoyl CoA desaturase-1 (SCD-1) and acetyl CoA carboxylase 1 (ACC-1) (Horton et al., 2002). 
The carbohydrate responsive element binding protein (ChREBP), another transcriptional factor, 
also plays an important role in inducing hepatic lipogenesis (Uyeda and Repa, 2006).   
Another major source of hepatic lipids is circulating free fatty acids (FFAs). Upon uptake 
by the hepatocytes, FFAs can be converted to triglycerides, when intrahepatic FFAs are in excess 
(Bradbury, 2006). As such, increased uptake of circulating FFA by hepatocytes can contribute to 
hepatic steatosis. The importance of FFAs in steatosis is supported by the clinical observation 
CHAPTER  II 
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that their concentration in plasma is often increased in various disorders associated with hepatic 
steatosis (Bradbury, 2006).  
Over 90% of plasma fatty acids are not free; they circulate as components of plasma 
lipoproteins (Figure 4). Very-density lipoproteins (VLDL) are the liver‟s primary vehicle for 
secreting triglyceride and transport lipids to peripheral tissues such as heart, skeletal muscle and 
adipose tissues. They undergo lipolysis, converting them to remnants, including intermediate-
density lipoprotein (IDL), low-density lipoprotein (LDL) and oxidized LDL (ox-LDL). These 
remnants are returned to the liver. Chylomicrons, dietary fats formed in the intestine, are 
hydrolyzed by lipoprotein lipase (LPL) leading to fatty acid delivery to peripheral tissues. 
Chylomicron remnants are also taken up by the liver. Hepatic uptake of lipoproteins is mediated 
via receptors, including the  
Figure 3 Hepatic lipid metabolism. In fed state, glucose is taken-up by liver to be metabolized, 
producing substrates required for de novo fatty acid synthesis. Within the liver, fatty acids are either 
oxidized or re-esterized into triglycerides for storage, which can be secreted as very-low density 
lipoprotein (VLDL) into blood stream. In turn, VLDL particles are directed toward difference tissues, 
such as muscle, heart and adipose tissues, depending on the tissue-specific availability of lipoprotein 
lipase (LPL). In addition, liver is responsible for uptake of triglyceride-derived free fatty acids. These 
actions of the liver are achieved by regulation of gene expression. The nuclear receptors and 
transcription factors involved in hepatic lipid metabolism are shown.  
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VLDL receptor (VLDLR), LDL receptor (LDLR), LDL receptor-related protein (LRP) and 
hepatic scavenger receptors including SR-A, SR-BI and CD36 (Figure 4).  
The fatty acid translocase CD36/FAT is the most widely studied cell surface receptor 
responsible for uptake of FFA. CD36 belongs to class B scavenger receptor highly present on the 
surface of a number of nonheptic cells and tissues, including monocytes/macrophages, 
endothelium, smooth muscle cells and differentiated adipocytes (Collot-Teixeira et al., 2007). 
Therefore, its role mediating FFA uptake has been recognized in nonhepatic tissues (Collot-
Teixeira et al., 2007; Febbraio and Silverstein, 2007). More recently, expression has been 
reported on hepatocytes under certain circumstances. For instance, CD36 has been documented 
to play an important role in hepatic steatosis due to its ability to translocate free fatty acids from 
the circulation into liver (Febbraio and Silverstein, 2007). In addition to CD36, fatty acid uptake 
can also be mediated by the liver fatty acid-binding protein (L-FABP) and fatty acid transport 
Figure 4 Hepatic lipid uptake.  The liver obtains lipid via lipoproteins and free fatty acids. The lipids 
are repacked and secreted as triglyceride-rich VLDL from the liver. Following hepatic secretion, 
lipoprotein lipase (LPL) hydrolyzes VLDL to release triglyceride and fatty acids in various tissues, 
including blood stream, adipose, muscle and heart. It further shrinks into intermediate-density 
lipoprotein (IDL) by hepatic lipase (HL) and cholesterol-rich LDL. Hepatic uptake of lipoproteins is 
mediated by the receptors, such as the VLDL receptor (VLDLR), LDL receptor (LDLR), LDL 
receptor-related protein (LRP) and hepatic scavenger receptors including SR-A, SR-B and CD36. 
CD36 is also capable of taking up fatty acids. Fatty acids are also transported into hepatocyte by fatty 
acid transport proteins (FATPs) and fatty acid binding proteins (FABPs).  
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protein (FATP) (Goldberg and Ginsberg, 2006). Mice deficient of L-FABP or FATP5 have been 
shown to be protective from Western diet-induced obesity and hepatic steatosis (Hubbard et al., 
2006; Newberry et al., 2006).  
Within the liver, fatty acids are either oxidized or re-esterized into triglycerides for 
storage. Fatty acids oxidation can occur in mitochondria, peroxisomes, or endoplasmic 
reticulum. Mitochondrial and peroxisomal oxidation is -oxidation primarily mediated by 
carnitine palmitoyltransferase 1 (CPT-1) and palmitoyl acyl-coenzyme A oxidase 1 (ACOX-1), 
respectively. The oxidation that occurs in the endoplasmic reticulum is -oxidation, which is 
catalyzed by the CYP4A enzymes (Reddy and Hashimoto, 2001). The liver triglycerides can be 
secreted as very-low density lipoprotein (VLDL) into the blood stream. VLDL particles are then 
directed to peripheral tissues, such as muscle, heart and adipose tissues, depending on the tissue-
specific availability of lipoprotein lipase (LPL).  
Despite the appreciation by the characterization of AhR null mice and identification of 
endogenous AhR ligands for the endobiotic function of AhR, the molecular mechanisms by 
which AhR affects normal physiology remain largely unknown. In order to study the 
physiological function of the receptor, a mutant that bears the constitutively activated AhR (CA-
AhR) was created by the deletion of the PAS-B domain in AhR and expressed in transgenic 
mice. CA-AhR expression driven by modified SV40 promoter caused the spontaneous 
development of stomach and liver cancer (Andersson et al., 2002; Moennikes et al., 2004). These 
mice also exhibited altered immune response (Andersson et al., 2003). T-cell specific expression 
of CA-AhR by CD2 promoter caused thymus involution and suppressed immunization-induced 
T-cell or B-cell expansion (Nohara et al., 2005). On the other hand, keratocyte-specific 
expression of CA-AhR by K14 promoter provoked an immune response accompanied by 
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inflammatory skin lesions (Tauchi et al., 2005).  In this chapter, using genetic and 
pharmacological models of AhR activation, we showed that liver and intestine-specific activation 
of AhR had a marked effect on metabolic functions, including the induction of hepatic steatosis 
even when mice were maintained on a regular chow diet.       
2.2 METHODS 
Chemicals 
TCDD (Cat#ED-901-C), Indigo (Cat#229296) and FICZ (Cat#GR206) were respectively 
purchased from Cambridge Isotope Laboratory (Andover, MA), Sigma (St Louise, MO) and 
BioMol (Plymouth Meeting, PA). Other chemicals were purchased from Sigma if not specified. 
  
Animals, drug treatment, and body composition analysis 
To generate the Tet-off transgenic system, CA-AhR was subcloned into the TetRE transgene 
cassette (Saini et al., 2004). Transgenic mice were produced at the University of Pittsburgh 
Transgenic Core Facility. The integration and copy numbers of the transgene were evaluated by 
Southern blot analysis. CA-AhR founder mice were bred with FABP-tTA transgenic mice (Line 
71) to generate the TRE-CA-AhR/FABP-tTA bi-transgenic mice. When necessary, doxycycline 
(2 mg/ml) was given in drinking water containing 5% sucrose. CD36
-/-
 mice (Febbraio et al., 
1999) and AhR
-/-
 mice (Fernandez-Salguero et al., 1995) in C57BL/6J background have been 
previously described. Transgenic mice and their same background and sex WT controls were 
used for all experiments. When necessary, mice received a single gavage of vehicle or TCDD 
(30 g/kg, dissolved in corn oil) and were sacrificed 7 days later. Liver paraffin sections (5 m) 
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and frozen sections (10 m) were used for H&E and Oil-red O staining, respectively. Mouse 
body composition was analyzed by using EchoMRI-100™ from Echo Medical Systems 
(Houston, TX). The use of mice in this study was approved by the University of Pittsburgh 
Institutional Animal Care and Use Committee. 
 
Plasmid constructs, reporter gene assay, and AhR siRNA transfection  
CA-AhR was constructed as described by others (McGuire et al., 2001). Briefly, mouse AhR 
cDNA was amplified by PCR using primers designed to yield fragments of AhR encoding 
codons 1-287 and 422-805, respectively. The fragments were digested with SmaI/XhoI and 
XhoI/NheI, respectively and subcloned into the pCMX-PL2 expression vector. The human CD36 
promoter (nt -1961 to +57) construct was PCR-amplified using the follow primers: 5‟-
GGTACCTCAAAATATGGTGGGTGCATAG-3‟ and 5‟-
CCCGGGCAATTCTTAATAGGATC-3‟. The mouse CD36 promoter (nt -1411 to +56) was 
PCR-amplified using the following primers: 5‟-GGCGCTAGCGTGTTGGAAACCTAGCTC-3‟ 
and 5‟-GGCAAGCTTCTGTGAAGAAGAAAAAG-3‟. The DRE mutant CD36 promoters were 
generated by PCR extension (Zhou et al., 2006). All promoters were cloned into pGL3-basic 
vector containing a luciferase reporter gene. CV-1 and HepG2 cells were transfected in 48-well 
cell culture plates using DOTAP and polyethyleneimine polymer transfection agents, 
respectively (Lee et al., 2008a). Transfected cells were then treated with drugs in medium 
containing 10% charcoal/dextran-stripped FBS for 24 hrs before harvesting for luciferase and -
gal assays. Transfection efficiency was normalized against -gal activity. AhR siRNA 
transfection was carried out using Lipofectamine 2000 as we have previously described (Lee et 
al., 2008a). The human AhR siRNA was added at the final concentration of 10nM in 
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transfection. The human AhR siRNA (Cat#SI02780148) and a control scrambled siRNA 
(Cat#1027280) were purchased from QIAGEN (Valencia, CA). Cells were transfected with 
siRNA for 5 hrs, and incubated in medium containing 10% FBS for 2 days.  
 
Human and mouse primary hepatocyte preparation 
Human primary hepatocytes isolated by collagenase perfusion were obtained from Dr. Steve 
Strom through the Liver Tissue Procurement and Distribution System (LTPDS). Mouse 
hepatocytes were prepared by collagenase perfusion (Wada et al., 2008). Cells were plated in 6-
well plate or 6-cm dish and maintained in the hepatocyte maintenance medium from Cambrex 
BioScience (Walkersville, MA). After overnight incubation, cells were treated with appropriate 
drugs for 24 hrs before harvesting.  
 
Northern blot and real-time RT-PCR analysis 
Total RNA was isolated using the TRIZOL reagent from Invitrogen (Carlsbad, CA). Northern 
hybridization using 
32
P-labeled cDNA probe was carried out as described (Lee et al., 2008a). For 
the real-time PCR analysis, reverse transcription was performed with random hexamer primers 
and Superscript RT III enzyme from Invitrogen. SYBR Green-based real-time PCR was 
performed with the ABI 7300 Real-Time PCR System. Data was normalized against control 
cyclophillin. Sequences of the real-time PCR probes are listed in Appendix A.  
 
Western blot analysis 
Liver extracts were prepared by homogenizing tissues in buffer A (20 mM Hepes pH=7.45, 150 
mM KCl, 10% glycerol, 0.1 mM EDTA) containing protease inhibitor (Sigma, P8340). The 
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protein concentrations were determined by using the BCA kit from Pierce (Rockford, IL). For 
ApoB immunoblotting, 3 l of plasma or 100 g of liver extracts were separated on 6% SDS-
PAGE gel and transferred onto nitrocellulose membrane. Membranes were blocked with 5 % 
non-fat milk in PBST (0.1 % Tween 20 in PBS) for 1 hr and then incubated with primary 
antibody overnight at 4°C. Antibody against ApoB100 (H-15, 1:200 dilution) and ApoB48 (S-
18, 1:200 dilution) were purchased from Santa Cruz. For CD36 and PCNA immunoblotting, 100 
g of liver extracts were separated on 10% SDS-PAGE gel and transferred onto PVDF 
membrane and blotted with CD36 antibody (NB400-144, 1:1500 dilution) purchased from Novus 
Biologicals (Littleton, CO) and PCNA antibody (VP-P980, 1:500 dilution) from Vector 
(Burlingame, CA). For AhR immunoblotting, Huh-7 cells were harvested in lysis buffer (22 mM 
Tricine, 1% Triton X-100, 10 % glycerol, 5 mM DTT, 8 mM MgCl2, 4 mM EGTA, 0.4 mM 
PMSF). Proteins were separated on 8% SDS-PAGE gel. After transfer to PVDF membrane, 
immunoblotting was performed using antibodies against AhR from BioMol (SA-210, 1:1000 
dilution) and -actin from Sigma (A1978, 1:5000 dilution). 
 
Electrophoretic mobility shift assay (EMSA)  
EMSA was carried out using receptor proteins by in vitro transcription/translation (TNT) as 
previously described (Saini et al., 2004). Oligonucleotide sequences for CD36/DREs and their 
mutant variants are labeled in the Figure 14A. Protein-DNA complex were resolved by 
electrophoresis through 8% polyacrylamide gel in 0.5 X TBE at 4 °C for 3-4 hrs.  
 
Measurement of circulating and tissue lipids 
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Blood samples were collected into an EDTA containing tube and centrifuged at room 
temperature to collect plasma. Liver tissues were homogenized and lipids were extracted as 
previously described (Zhou et al., 2006). Briefly, 250 mg of liver was homogenized in 2 mL of 
buffer containing 18 mM Tris (pH 7.5), 300 mM mannitol, 50 mM EGTA, and 0.1 mM PMSF. 
Lipids were extracted by incubating 400 L of homogenate overnight in chloroform/methanol 
mixture (2:1 v/v) followed by adding distilled water to separate the organic phase containing 
tissue lipids. The organic phase was dried under nitrogen gas. The lipid pellets were then 
dissolved in 120 l of tert-butanol and 80 l of Triton X 114:methanol (2:1 v/v) mixture. Plasma 
and liver concentrations of triglycerides and cholesterol were determined using assay kits from 
Stanbio (Boerne, TX). Plasma and liver free fatty acids were measured by using an assay kit 
from Biovision (Mountain View, CA). Plasma -hydroxybutyrate was measured by an 
RANBUT kit from Randox (Crumlin, UK). Glucose levels were measured by using a 
glucometer.    
 
Measurement of lipid peroxidation in liver 
Tissue levels of malondialdehyde (MDA) were determined as an index of lipid peroxidation. 
Liver lipid homogenates were added to a reaction mixture containing 0.67% thiobarbituric acid 
(TBA), boiled for 1 h at 95ºC, and then centrifuged at 3,000 g for 10 min. Supernatant 
absorbance was measured by spectrophotometry at 532 nm and compared with a standard curve 
prepared from different concentrations of 1,1,3,3-tetramethoxypropane.  
 
TUNEL assay  
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Apoptosis was determined in liver paraffin sections by TUNEL assay using an assay kit (Cat # 
11 684 795 910) from Roche Diagnostics (Indianapolis, IN). Apoptotic cells were detected by 
fluorescein staining, and the nuclei were counterstained with Propidium Iodide.   
 
Measurement of intestinal fat absorption  
Mice were fasted for 16hrs then orally given 10 ml/kg of olive oil. Plasma samples were 
collected at 0, 3, 6, 9, 12 hrs after olive oil administration. Plasma triglyceride levels were 
measured as described above.  
 
Free fatty acid uptake experiment  
Huh-7 cells were seeded into chamber slides (Cat#154526) from Nalge (Naperville, IL) at a 
density of 2.5×10
4
/per well and incubated overnight before treatment with TCDD for 24 hrs. 
Primary mouse hepatocytes were seeded into 6-cm culture dishes and incubated overnight before 
treatment with DOX for 24 hrs. Cells were then serum starved for 3 hrs and rinsed with PBS. 
Cells were then incubated with 500 nM of 4,4-difluoro-5,7-dimethyl-4-bora-3, 4-diaza-s-
indacene-3-hexadecanoic acid (BODIPY-C16) from Molecular Probes/Invitrogen for 3 mins in 
PBS, rinsed with ice-cold PBS three times, and fixed in ice-cold 4% paraformaldehyde (pH 7.4) 
for 30 mins. After washing with PBS twice, cells were cover slipped in mounting medium 
containing DAPI. The fluorescence intensity was quantified by using the NIH Image J software 
(http://rsbweb.nih.gov/ij).     
 
Measurement of peroxisomal -oxidation 
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Liver tissues were homogenized in 0.25 M sucrose (20% w/v) and homogenates were used for 
determination of peroxisomal -oxidation by monitoring the rate of NAD+ reduction to NADH 
at 340 nm using palmitoyl-CoA as a substrate in the presence of KCN, which completely inhibits 
mitochondrial -oxidation. The assay mixture contained 50 mM Tris-HCl buffer (pH 8.0), 0.2 
mM NAD, 0.01 mM FAD, 0.1 mM CoA, 12 mM DTT, 0.15 mg/ml BSA, 0.01% Triton X-100, 
1.0 mM KCN and 0.01 mM palmitoyl-CoA as previously described (Lazarow and De Duve, 
1976; Youssef et al., 1997). NADH formation was quantitated using an extinction coefficient of 
6.22 cm
−1
 mM
−1
. 
 
Measurement of VLDL secretion rate 
VLDL secretion rate in vivo was measured as previously described (Merkel et al., 1998; 
Uchiyama et al., 2006). Briefly, 16 hr-fasted mice were injected with Triton WR1339 (500 
mg/kg in saline) via the tail vein. Plasma samples were collected at 0 and 90 min after Triton 
WR1339 injection, and triglyceride levels were then measured as described above.  
 
Statistical analysis 
Results were presented as means ± SD.  Animal numbers are shown in figure or figure legends. 
Comparisons between groups were performed using the Student‟s t test or one-way ANOVA 
where appropriate. * P<0.05 was considered statistically significant. N.S. represents statistically 
not significant.    
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2.3 RESULTS 
2.3.1 Creation and characterization of the constitutively activated AhR (CA-AhR)  
We constructed a constitutively activated AhR (CA-AhR) by deleting the minimal ligand-
binding domain (amino acids 287-422) of the AhR (Figure 5). This mutant AhR has been shown 
to be constitutively activated (McGuire et al., 2001). Expression levels of CA-AhR were 
comparable to those of wild type AhR (Figure 6A). CA-AhR displayed an efficient binding to 
the dioxin response element (DRE) derived from the Cyp1a1 gene, as shown by eletrophoretic 
mobility shift assay (EMSA) (Figure 6B).  
To determine functionality of the CA-AhR mutant protein, CV-1 cells were transiently 
transfected with the DRE-driven luciferase reporter gene pGud-luc (Han et al., 1994), together 
with expression vectors of AhR and Arnt. As shown in Figure 6C, CA-AhR activated the 
reporter gene in the absence of an exogenously added AhR ligand, and addition of the AhR 
ligand 3-methylchoranethrene (3-MC) (Denison and Nagy, 2003) had little further effect. This 
was in contrast to the wild type AhR receptor, which exhibited substantial ligand-dependent 
activation as expected (Figure 6C). CA-AhR also activated the pGud-luc reporter gene without a 
ligand treatment when both plasmids were transfected in vivo into mouse liver by a 
Figure 5 Schematic representation and domain structure of the wild type (WT) AhR and 
constitutively activated (CA-AhR) AhR. bHLH, basic helix-loop-helix, PAS, Per-Arnt-Sim. 
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hydrodynamic gene delivery system (Figure 6D and 6E). The reporter gene activity was 
increased ~5 fold by CA-AhR in the absence of TCDD compared to transfecting wild type AhR 
(Figure 6D) and the AhR-responsive gene Cyp1a2 mRNA levels were increased in mice injected 
with CA-AhR, as compared to wild type AhR (Figure 6E). Thus, CA-AhR transgene is 
transcriptionally active with ligand-independent manner in vitro and in vivo.   
 
Figure 6 Characterization of a constitutively activated AhR (CA-AhR). (A) In vitro translated, 
[
35
S]methionine-labeled wild type AhR or CA-AhR proteins. The positions of protein markers are 
shown on the left. (B) CA-AhR-Arnt heterodimers bind to Cyp1a1/DRE as shown by EMSA. 
Arrowhead indicates specific bands. (C) CA-AhR activates the AhR-responsive pGud-Luc 
reporter gene in a ligand independent manner. 3-MC, 3-methylchoranethrene. The drug 
concentration is 2 M. (D and E) Eight week-old CD-1 female mice were treated with i.p. 
injection of DMSO or TCDD (50g/kg). After one hour, mice were injected via the tail vein with 
5g of AhR or CA-AhR and 10g of pGud-luc in saline. Six hours after injection of DNA, mice 
were sacrificed, the liver was collected, luciferase activity in extracts was measured (D) and the 
expression of Cyp1a2 was detected by Northern blot (E). The control lane (Ctrl) represents 
activity from reporter gene alone and empty expression vector.                
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2.3.2 Generation of conditional tetracycline inducible transgenic mice expressing CA-
AhR in the liver and intestine 
To examine the biological consequences of AhR activation in vivo, we generated tetracycline 
inducible CA-AhR transgenic mice expressing the constitutively activated AhR (CA-AhR) 
(Figure 7A). Our “Tet-off” transgenic system is composed of two transgenic lines with one line 
(TetRE-CA-AhR) expressing CA-AhR under the control of a minimal cytomegalovirus promoter 
(PCMV) fused to the tetracycline responsive element (TRE), and the other line (FABP-tTA) 
expressing the tetracycline transcriptional activator (tTA) constitutively and exclusively in liver 
and intestine under the control of the fatty acid binding protein (FABP) promoter (Zhou et al., 
2006). We predict that in mice carrying both transgenes, tTA will bind to TRE and induce the 
expression of CA-AhR in the absence of doxycycline (DOX). In the same animals, treatment 
with DOX will dissociate tTA from TRE, leading to the silencing of CA-AhR expression (Figure 
7A). To determine whether CA-AhR is transcriptionally active under tetracycline inducible 
system, we analyzed reporter gene activity by transient transfection of TRE-CA-AhR and Arnt, 
together with CMX-tTA or CMX-rtTA that expresses the reverse tTA in CV-1 cells (Figure 7B). 
Coexpression of tTA with TRE-CA-AhR resulted in induction of reporter gene expression in the 
absence of DOX, however DOX treatment failed to stimulate reporter gene activity (Figure 7B). 
The dependence of DOX for induction of CA-AhR was also confirmed by expression of rtTA, 
which binds to TRE in the presence of DOX resulting in induction of CA-AhR (Figure 7B).   
Pronuclear microinjection of the FABP-tTA transgene yielded four founder mice that led 
to the establishment of four independent tTA lines, among which Line 71 was chosen for 
subsequent cross-breeding due to the high expression of tTA in both the liver and intestine (data 
not shown). Microinjection of the TRE-CA-AhR transgene produced six founders determined by 
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PCR (Figure 7C). The integration and copy numbers of the transgene were evaluated by 
Southern blot analysis (Figure 7D). Cross-breeding of the TRE-CA-AhR founders with FABP- 
tTA mice yielded four bi-transgenic lines, among which Lines 4 and 6 were found to express 
CA-AhR in the liver and small intestine of both sexes (Figure 8A). The bi-transgenic mice also 
showed an increased mRNA expression of Cyp1a2, a known AhR target gene (Figure 8A). 
Interestingly, Line 3 expressed CA-AhR in the liver but not in the intestine, whereas Line 8 
expressed CA-AhR in the liver and intestine of males but not females (Figure 8A).  Line 4 was 
chosen for further characterization and most of the subsequent experiments.  
Figure 7 Conditional expression of CA-AhR under the tetracycline inducible system. (A) Schematic 
representation of the Tet-off FABP-tTA/TRE-CA-AhR transgenic system. DOX, doxycycline; FABP, 
fatty acid binding protein; PCMV, minimal CMV promoter; TRE, tetracycline responsive element; 
tTA, tetracycline transcriptional activator. (B) CV-1 cells were transiently transfected with pGud-luc 
and TRE-CA-AhR together with expression vectors of either tTA or rtTA (reverse tetracycline 
transcription activator: “Tet-On”) in the presence/absence of DOX (1g/mL). The reporter gene 
expression by AhR or CA-AhR was included as controls. The control lane (Ctrl) represents activity 
from reporter gene alone and empty expression vector. (C and D) Generation of TRE-CA-AhR 
transgenic mice. Integration and copy number of transgene was verified by PCR (C) and Southern blot 
analysis (D) of genomic DNA from tail.  
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As expected, the expression of CA-AhR and induced Cyp1a2 gene expression were 
abolished when mice were given DOX-laced drinking water for one week (Figure 8B). CA-AhR 
was specifically expressed in liver and intestine, consistent with the tissue specificity of the 
FABP promoter (Zhou et al., 2006). No transgene expression was detected in several other AhR-
expressing tissues, such as adipose tissue, stomach, kidney, lung, thymus, muscle and heart 
(Figure 8C). The transgenic mice were viable and fertile. The serum level of alanine 
aminotransferase (ALT), an indicator of hepatotoxicity, was not significantly increased in the  
Figure 8 Generation of transgenic mice expressing CA-AhR in the liver and intestine. (A) Hepatic and intestinal 
expression of CA-AhR and induction of Cyp1a2 as shown by Northern blot analysis. Gapdh was shown for 
loading control. (B) Treatment of bi-transgenic mice with DOX for 1 week silenced both the expression of CA-
AhR and induction of Cyp1a2. (C) CA-AhR transgene is not expressed in a panel of tissues outside of the liver 
and intestine of the transgenic mice, as determined by real-time PCR and semi-quantitative RT-PCR (insert). 
Cyclophilin is included as a loading control. (D) Activation of AhR in CA-AhR mice was not associated with 
obvious hepatotoxicity at 5-6 weeks of age. Serum levels of ALT were measured in female mice. Mice in TCDD 
treated group received a single p.o. dose of TCDD (30mg/kg) and sacrificed 7 days after.  
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transgenic mice (Figure 8D), suggesting that the genetic activation of AhR was not associated 
with obvious hepatotoxicity. This is in contrast to the known toxicity in mice treated with the 
xenobiotic AhR agonist TCDD (Figure 8D and (Walisser et al., 2005)).  
2.3.3 CA-AhR transgenic mice developed hepatic steatosis and showed decreased body 
weight and fat mass  
The CA-AhR transgenic mice showed hepatomegaly. At 5 weeks, the liver accounted for 5.08% 
of total body weight in WT females, and 5.64% in transgenic females, an increase of 11% 
(Figure 9A). H&E staining showed the hepatocytes from transgenic mice had a vacuolated-
cytoplasmic appearance (Figure 9B), suggestive of lipid deposition. Oil-red O staining confirmed 
the increased lipid droplets in hepatocytes of transgenic mice (Figure 9B). Liver tissue 
triglyceride, but not cholesterol and free fatty acid, increased in concentration by 2.5 fold in 
transgenic mice (Figure 10A). The steatotic phenotype depended on AhR activation, because 
treatment of transgenic mice with DOX for 2 weeks normalized the liver Oil-red O staining and 
triglyceride content (Figure 9B and 10A). Hepatic steatosis was also observed in Line 3, in  
Figure 9 CA-AhR transgenic mice showed phenotype of hepatic steatosis. (A) The liver weight (LW) 
was measured as percentage of the total body weight (BW). (B) Liver sections of wild type (WT) and 
CA-AhR mice were stained with H&E (upper panels) or Oil-Red-O (lower panels).  
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which CA-AhR was expressed only in the liver (data not shown), suggesting that activation of 
AhR in the liver was sufficient for the development of steatosis. As consistent with hepatic 
cholesterol levels, plasma cholesterol levels were unchanged in CA-AhR mice (Figure 10B). 
Interestingly, despite hepatic accumulation of triglycerides, the plasma level of triglycerides was 
Figure 10 CA-AhR transgenic mice showed metabolic abnormalities. (A) Measurements of hepatic 
cholesterol, triglyceride and free fatty acid (FFA) in the liver. n=4 per each group (B-D) Plasma cholesterol 
(B), triglyceride (C) and FFA (D) levels were measured in overnight fasted mice. (E) Body weight (F) Food 
intake. Repeated 4 times (G) Rectal body temperature, repeated 4 times (H) Percentage of whole-body fat 
content and lean body mass were analyzed by MRI. (I) Circulating glucose levels were determined from 
fasting and fed mice. (A-D) 5-6 week-old female mice were used. (E-I) Two-month old female mice were 
used.  Mice numbers are labeled.  
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not increased in the transgenic mice (Figure 10C). Plasma free fatty acid levels remained 
unchanged in the transgenic mice (Figure 10D).  
The transgenic mice also showed other metabolic abnormalities. The transgenic mice, 
which were in the FVB background and fed with a standard rodent chow, had modest but 
significantly decreased body weight compared to their WT littermates (Figure 10E). CA-AhR 
mice were hypophagic (Figure 10F). Body temperature was increased in CA-AhR mice (Figure 
10G). Body composition analysis by MRI showed that the transgenic mice had a 23% decrease 
in fat mass and 4% increase in lean mass when measured as percentages of body weight (Figure 
10H). Circulating glucose levels were significantly lower in both fasted and fed transgenic mice 
(Figure 10I).  
2.3.4 Activation of AhR induced fatty acid translocase CD36 and uptake of fatty acid   
To understand the mechanism by which AhR promotes steatosis, we profiled the expression of 
genes in the liver and intestine by Affymetrix microarray analysis. The microarray results 
showed that 2.9% and 2.3% of genes were upregulated and downregulated in the livers of CA-
AhR mice, respectively (Appendix B and Table 1). The microarray results on the intestine are 
summarized in Appendix C and Table 2. Our initial Affymetrix microarray analysis showed that 
the expression of CD36, a scavenger receptor capable of high affinity uptake of fatty acids, was 
induced in the liver of CA-AhR transgenic mice. In contrast, the expression of Srebp-1c and its 
target lipogenic enzymes Fas, Acc and Scd-1 was unchanged (data not shown). The microarray 
induction of hepatic CD36 mRNA expression by AhR was confirmed by both real-time PCR 
(Figure 11A) and Northern blot analysis (Figure 11B). Consistent with the inducible levels in 
CD36 mRNA expression, CD36 protein expression (Figure 11C) was significantly increased in 
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livers from CA-AhR mice. The regulation of CD36 was transgene-dependent, because the 
induction was abolished after DOX treatment (Figure 11A), presumably due to the silencing of 
the transgene. Interestingly, AhR-mediated CD36 regulation appeared to be tissue specific, 
because the intestinal CD36 expression remained unchanged (Figure 11D), despite the transgene 
expression and Cyp1a2 induction in this tissue (Figure 8). The hepatic induction of CD36 was 
also observed in C57BL/6J mice treated with TCDD (Figure 11E). Again, the regulation 
appeared to be tissue-specific, because TCDD had little effect on CD36 expression in skeletal 
muscle (Figure 11F). The induction of CD36 by TCDD was largely abolished in AhR
-/-
 mice, as 
was the induction of Cyp1a2 (Figure 11G). These results demonstrated that the TCDD effect on 
CD36 gene expression was AhR-dependent. In addition to CD36, the hepatic uptake of fatty  
Figure 11 Activation of AhR induced expression of CD36 in liver. (A-B) Real-time PCR analysis (A) and 
Northern blot analysis (B) on the hepatic expression of CD36 mRNA in two-month-old female CA-AhR mice. 
When applicable, mice were treated with DOX (2 mg/ml in drinking water) for 2 weeks before sacrificing. N=4 for 
each group. (C) Western blot analysis on the hepatic expression of CD36 proteins in two-month-old male CA-AhR 
mice. (D) Real-time PCR analysis on intestinal CD36 expression. N=3 for each group. (E and F) Real-time PCR 
analysis on the liver (E) and skeletal muscle (F) mRNA expression of CD36 in 8 week-old female C57BL/6J mice 
treated with vehicle or TCDD (30 g/kg, p.o.) for 3 days (3d, n=4 for each group) or 7 days (7d, n=8 for each 
group). (G) The induction of CD36 by TCDD (10 g/kg TCDD, 1day) was abolished in AhR-/- mice.   
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acids can also be facilitated by the intracellular fatty acid transfer proteins (FATPs) (Goldberg 
and Ginsberg, 2006). Cell surface lipoprotein receptors, such as VLDLR, LDLR, SR-A and SR-
B, also contribute to the hepatic uptake of lipids. As shown in Figure 12A, the expression of 
Fatp1 and Fatp2 was modestly, but significantly, increased in transgenic mice; whereas the 
expression of Fatps 3-5, VLDLR, LDLR, SR-A and SR-B was not affected.  
To determine whether the elevated expression of CD36, Fatp1 and Fatp2 led to an 
increased hepatic fatty acid uptake, primary hepatocytes were isolated and evaluated for fatty 
acid uptake by incubating cells with 4,4-difluoro-5,7-dimethyl-4-bora-3, 4-diaza-s-indacene-
3-hexadecanoic acid (BODIPY-C16), a fluorescent fatty acid analog (Shaffer et al., 1994). As 
 
Figure 12 Activation of AhR induced the free fatty acid uptake in mouse hepatocytes. (A) Real-time PCR analysis 
on the hepatic expression of free fatty acid transporter proteins (Fatps), very-low density lipoprotein receptor 
(VLDLR), low density lipoprotein receptor (LDLR), scavenger receptor A and B (SR-A and SR-B) in CA-AhR 
mice (n=6 for each group). (B and C) Free fatty acid uptake in primary mouse hepatocytes is monitored by the 
uptake of 4,4-difluoro-5,7-dimethyl-4-bora-3, 4-diaza-s-indacene-3-hexadecanoic acid (BODIPY-C16). (B) 
Top and bottom panels are fluorescence and phase contrast images of the cells, respectively. DOX concentration is 
1 g/ml. (C) Quantification of BODIPY-C16 uptake in (B). AU, arbitrary unit. 
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shown in Figure 12B and 12C, the BODIPY-C16 uptake by hepatocytes derived from the 
transgenic mice was markedly increased compared to those isolated from the WT mice. The 
transgenic effect on BODIPY-C16 uptake was largely abrogated upon DOX treatment.  
2.3.5 Treatment of AhR ligands induced CD36 and increased free fatty acid uptake in 
human liver cells 
Treatment of primary human hepatocytes (Figure 13A) or Huh-7 human hepatoma cells (Figure 
13B) with TCDD (10 nM) for 24 hrs induced the mRNA expression of CD36, suggesting that the 
AhR effect on CD36 gene expression is conserved in human liver cells. In the same TCDD-
treated cells, the respective expression of CYP1A1 and CYP3A4 was induced and reduced as 
expected (Shaban et al., 2005). Activation of CD36 gene expression was also observed in Huh-7 
cells treated with the various AhR ligands including endogenous AhR agonists Indigo (Adachi et 
al., 2001) and FICZ (Rannug et al., 1995) (Figure 13C). Moreover, the induction of CD36 by 
FICZ in Huh-7 cells was significantly inhibited when cells were transfected with AhR siRNA 
(Figure 13D). The efficiency of AhR siRNA knockdown was confirmed by real-time PCR and 
Western blot analysis (Figure 13E). Also in Huh-7 cells, treatment with TCDD (10 nM) 
increased the uptake of BODIPY-C16, but this effect was abolished when cells were transfected 
with AhR siRNA (Figure 13F and 13G). 
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Figure 13 Treatment of human hepatocytes with AhR agonists induced the expression of CD36 and increased 
free fatty acid uptake. (A-C) Primary human hepatocyte (A) and Huh-7 human hepatoma cells (B and C) were 
treated with indicated drugs for 24 hrs before RNA harvesting and real-time PCR analysis. (D) The FICZ-
inducible activation of CD36 gene expression was abolished in Huh-7 cells transfected with AhR siRNA. (E) 
The knockdown of AhR in siAhR-transfected cells was confirmed by real-time PCR and Western blot analysis 
(insert). (F) Fatty acid uptake is monitored by the uptake of BODIPY-C16. (G) Quantification of BODIPY-
C16 uptake in (F). The drug concentrations are TCDD, 10 nM; FICZ, 200 nM; Indigo, 10 M; -NF, 10M; 
3-MC, 2 M. 
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2.3.6 The mouse and human CD36 gene promoters are transcriptional targets of AhR 
To determine the molecular mechanism by which AhR regulates CD36, the mouse (nt -1411 to 
+56) and human (nt -1961 to +57) CD36 gene promoters were cloned and analyzed for their 
regulation by AhR. Inspection of the promoter sequences revealed several putative DREs (Figure 
14A) whose binding to AhR-Arnt heterodimers was confirmed by EMSA (Figure 14B). 
Consistent with the EMSA results, luciferase reporter genes containing the mouse (pGL-mCD36) 
or human (pGL-hCD36) CD36 promoters were activated by wild type AhR in response to the 
various AhR agonist (Figure 14C). Both the mouse and human CD36 gene promoters were also 
activated by CA-AhR without an exogenously added ligand (Figure 14D and 14E). Mutation of 
DREs abrogated AhR-dependent transactivation (Figure 14D and 14E).  
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Figure 14 The human and mouse CD36 genes are transcriptional targets of AhR. (A) The sequences of 
dioxin responsive elements (DREs) in the human and mouse CD36 gene promoters. (B)  EMSA was 
performed using in vitro transcribed and translated proteins and 
32
P-labeled DREs. (C) Activation of 
hCD36 and mCD36 promoter reporter genes by the exogenous and endogenous AhR agonists. (D and E) 
Mutation of DREs in hCD36 and mCD36 promoter reporter genes abolished AhR-dependent 
transactivation in the presence of 3-MC or CA-AhR-dependent transactivation without an exogenously 
added ligand. HepG2 cells were co-transfected with indicated reporters and receptors. Transfected cells 
were treated with vehicle (DMSO), Indigo (10M), FICZ (200nM), -NF (10M), TCDD (10nM) or 3-
MC (2 M) for 24 hrs before luciferase assay. The transfection efficiency was normalized against the co-
transfected -gal activity.  
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2.3.7 Loss of CD36 in mice inhibited the steatotic effect of an AhR agonist 
Having established CD36 as an AhR target gene, we went on to determine whether the 
expression and regulation of CD36 were required for the steatotic effect of AhR. In this 
experiment, we first determined whether the expression of CD36 is required for fatty acid uptake 
dependent on AhR activation. As shown in Figure 15A and 15B, the BODIPY-C16 uptake by 
primary hepatocytes derived from the WT was significantly increased in the presence of TCDD. 
In sharp contrast, the BODIPY-C16 uptake was abolished in TCDD-treated hepatocytes derived 
from CD36
-/-
 mice (Figure 15A and 15B).  
To assess if the lack of CD36 expression could rescue the steatotic effect by AhR in vivo, 
WT and CD36
-/-
 female mice were treated with a single dose of TCDD (30 g/kg) and the mice 
were sacrificed 7 days later. Treatment of WT mice with TCDD induced hepatomegaly and 
hepatic steatosis as shown by Oil-red O staining (Figure 15C) and measurement of tissue 
triglyceride content (Figure 15D). These results were consistent with those observed in the CA-
AhR transgenic mice, as well as those published by others (Boverhof et al., 2006). Interestingly, 
hepatic steatosis phenotypes were inhibited in CD36
-/-
 mice (Figure 15C and 15D). In female 
mice, increase of  hepatic triglyceride levels in TCDD-treated CD36
-/-
 mice were abolished 
compared their WT counterparts, whereas loss of CD36 alone, in the absence of TCDD, had little 
effect on the liver triglyceride content (Figure 15C).  These results suggest that CD36 acts as a 
hepatic fatty acid translocator in the response of AhR activation. Interestingly, the lack of 
TCDD-induced triglyceride increase in liver was more prominent in female than male CD36
-/-
 
mice (data not shown). TCDD treatment significantly decreased plasma triglyceride levels in 
both female (Figure 15E). However, the decrease of triglyceride levels by TCDD was not seen in 
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CD36
-/-
 female mice (Figure 15E). These results suggest that CD36 is required for the steatotic 
effect of AhR agonists. 
  
Figure 15 Loss of CD36 in mice inhibited the steatotic effect of an AhR agonist. (A and B) Free fatty acid 
uptake in primary mouse hepatocytes from WT and CD36
-/-
 treated with vehicle (Veh) or TCDD is 
monitored by the uptake of BODIPY-C16. Top and bottom panels are fluorescence and phase contrast 
images of the cells, respectively (A). TCDD concentration is 10 nM. (B) Quantification of BODIPY-C16 
uptake in (A). AU, arbitrary unit. (C) Oil-red O staining on liver sections of WT or CD36
-/-
 mice treated 
with vehicle (Veh) or TCDD. (D) Measurements of hepatic triglyceride levels. (E) Measurements of plasma 
triglyceride levels. Two-month old female mice were gavaged with a single dose of TCDD (30 g/kg) for 7 
days and sacrificed after 16 hrs of fasting 
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2.3.8 Treatment with AhR agonist inhibited VLDL-triglyceride secretion  
VLDL secretion is important for the export of triglycerides from hepatocytes. The accumulation  
of hepatic triglycerides and lack of increases in circulating triglycerides prompted us to 
determine whether the activation of AhR inhibits VLDL-triglyceride secretion. VLDL-
triglyceride secretion rate in vivo was measured by injecting fasted mice with Triton WR1339 
(500 mg/kg in saline) via the tail vein to inhibit lipoprotein lipase activity and thus preventing 
VLDL hydrolysis. Blood samples were collected at 0 and 90 min after Triton WR1339 injection 
and plasma triglyceride levels were measured. As shown in Figure 16A, treatment of WT mice 
with TCDD (30 g/kg, single p.o. dose) for 7 days resulted in a significant inhibition of VLDL-
triglyceride secretion. The hepatic mRNA expression of ApoB100, an apolipoprotein important 
for the structural integrity of VLDL (Fisher and Ginsberg, 2002), was significantly decreased in 
TCDD-treated WT mice (Figure 16B). The plasma levels of both ApoB100, but not ApoB48 
proteins were decreased in TCDD-treated mice (Figure 16C). In contrast, we observed normal 
Figure 16 Treatment with TCDD inhibited VLDL-triglyceride secretion. (A) Two-month old 
female mice were treated with a single dose of TCDD (30 g/kg) for 7 days before measuring 
the VLDL-triglyceride (TG) secretion. Mice were fasted for 16 hrs before the assay. (B-C) 
Measurements of hepatic ApoB100 mRNA (B, shown is the real-time PCR result, n=3) and 
plasma ApoB protein (C, shown is the Western blot result) levels. *ns, non-specific band 
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VLDL-TG secretion rates in CA-AhR mice comparing to WT mice (Figure 17A). Neither the 
mRNA level of hepatic ApoB100, nor the protein levels of the hepatic and plasma ApoB100 
were altered in CA-AhR mice (Figure 17B and 17C). The expression of microsomal triglyceride 
transfer protein (MTP), a protein required for assembling ApoB with triglyceride and cholesteryl 
esters, remained unchanged in both TCDD treated and CA-AhR mice comparing their controls 
(data not shown).   
VLDL-triglyceride secretion in vivo remained impaired in CD36
-/-
 mice in response to 
TCDD (data not shown). The decreased VLDL-triglyceride secretion may have accounted for the 
reduced plasma levels of triglyceride found in both WT and CD36
-/-
 mice by TCDD whereas the 
observation was not seen in the CA-AhR mice.   
2.3.9 Activation of AhR impaired hepatic peroxisomal fatty acid -oxidation  
The suppression of PPARa positive regulator of fatty acid oxidation, and its target genes acyl-
coenzyme A oxidase 1 (Acox1), thiolase, long-chain Acyl CoA dehydrogenase (Lcad), and 
Cyp4a enzymes in transgenic mice was first suggested by the microarray analysis (Appendix B 
Figure 17 CA-AhR mice showed normal VLDL-triglyceride secretion. (A) VLDL-TG 
secretion, (B) hepatic ApoB100 mRNA expression and (C) hepatic and plasma ApoB protein 
levels were measured in CA-AhR transgenic mice. *ns, non-specific band 
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and Table 1). The suppression of these genes was confirmed by real-time PCR analysis (Figure 
18A). Consistent with suppression of Acox-1, the rate-limiting enzyme of peroxisomal -
oxidation, liver extracts from transgenic mice exhibited a significantly decreased peroxisomal -
oxidation when palmitoyl-CoA was used as the substrate (Figure 18B). Mitochondria -
oxidation determined by fasting plasma levels of -hydroxybutyrate, which is one of ketone 
bodies produced by mitochondria -oxidation, was not affected by activation of AhR (Figure 
18C).    
2.3.10 Activation of AhR decreased white adipose tissue (WAT) adiposity and increased 
WAT lypolysis 
The decreased fat mass in CA-AhR transgenic mice was first suggested in MRI body 
composition analysis (Figure 10H). Necropsy showed smaller omental fat (Figure 19A) and 
adipocyte hypotrophy (Figure 19B and 19C) in the transgenic mice. Treatment of WT mice with 
TCDD also decreased the omental fat mass (Figure 19D), consistent with a previous report 
(Phillips et al., 1995). Consistent with the inhibition of WAT adiposity, we found the mRNA 
Figure 18 Activation of AhR in transgenic mice inhibited hepatic peroxisomal fatty acid -oxidation. (A) 
Suppression of PPAR and its target genes involved in fatty acid oxidation in 2-month old female CA-AhR 
transgenic mice, as shown by real-time PCR analysis. N=6 for each group. (B) Inhibition of peroxisomal -oxidation 
in the liver extracts of transgenic mice. Palmitoyl-CoA was used as the substrate. (C) Plasma levels of -
hydroxybutyrate. Two-month old male mice were fasted for 16hr prior to collect plasma.   
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expression of adipose triglyceride lipase (ATGL) was significantly increased in the transgenic 
mice (Figure 19E) or TCDD-treated WT mice (Figure 19F), but the expression of hormone-
sensitive lipase (HSL) was unchanged in either group. Interestingly, TCDD effect on decrease 
the omental fat mass and increase in ATGL expression was compromised in CD36
-/-
 mice 
(Figure 19D and 19F).        
2.3.11 The effect of AhR in hepatic oxidative stress, proliferation, apoptosis and dietary fat 
absorption. 
To investigate whether activation of AhR affect on hepatic oxidative stress, we examined the 
status of various inflammatory parameters. Lipid peroxidation was measured by the thio- 
Figure 19 Activation of AhR in transgenic mice decreased white adipose tissue (WAT) adiposity, and 
increased WAT lipolysis. (A) Representative appearance of the omental fat in 8-week old female WT and 
transgenic mice. (B) H&E staining of epididymal fat. (C) Quantification of adipocyte size. (D) Omental 
fat tissue weight (WAT) was measured as percentage of total body weight (BW) in 2-month old male WT 
or CD36
-/- 
mice gavaged with vehicle (Veh) or TCDD (30 g/kg, p.o.) 7 days prior to being sacrificed 
(n=5 for each group). (E and F) Abdomen fat triglyceride lipase (ATGL) and hormone-sensitive lipase 
(HSL) mRNA expression as measured by real-time PCR analysis in transgenic mice (G, n=3 for each 
group), WT or CD36
-/- 
 mice treated with Veh or TCDD (H, n=5 for each group). 
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barbituric assay for malondialdehyde (MDA), which is an end product of lipid peroxidation. As 
shown in Figure 20A, activation of AhR caused three-fold increase of MDA concentrations in 
the liver. Enhanced lipid peroxidation in the liver of CA-AhR mice was abolished when DOX 
was administered in CA-AhR mice for 2 weeks, indicating that the effect is AhR dependent. 
Since cytokines are key mediators of hepatic inflammation and liver injury, we examined the 
effect of AhR in expression of cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor 
 (TNF), which are the 2 prototypical proinflammatory cytokines. As shown Figure 20B, we 
found increased expression of TNF, not IL-6, in the liver of CA-AhR mice.  
Figure 20 Effect of AhR in hepatic oxidative stress, proliferation, apoptosis and fat absorption. (A) Hepatic 
concentrations of malondialdehyde (MDA). Lipid homogenates were extracted from 5-6 week old female mice. 
DOX were treated for 2 weeks as indicated (n=3 each). (B) Hepatic mRNA expression of TNF and IL-6 as 
measured by real-time PCR analysis (n=6 for each group). (C) Apoptosis in the liver was measured by TUNEL 
assay. CV represents central vein in the liver (D) Levels of PCNA as a proliferation marker in mouse liver extract 
were determined by Western blotting. (E) Intestinal fat absorption was determined by measuring plasma triglyceride 
levels after oral gavage of olive oil (10mL/kg). Two-month old female mice were fasted prior to administration of 
olive oil.  
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Apoptosis is a common mechanism of liver injury and patients with NASH compared 
with simple steatosis showed increased numbers of terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate nick-end labeling (TUNEL)-positive cells (Tilg and 
Hotamisligil, 2006). At the age of 2 months in CA-AhR mice, no significant differences in 
hepatocytes apoptosis were observed (Figure 20C). Hepatic proliferation was evaluated by the 
proliferating cell nuclear antigen (PCNA) proliferation marker. As shown in Figure 20D, no 
enhanced expression of PCNA was observed in 2 month-old CA-AhR mice livers compared with 
WT controls.  
To determine whether activation of AhR in intestine alters dietary fat digestion and/or 
absorption since the transgene is expressed in the intestine, we orally administered the mice with 
olive oil and evaluated intestinal fat absorption in vivo. Plasma triglyceride levels were 
immediately increased after olive oil administration in both WT and CA-AhR mice (Figure 20E). 
Elevated plasma triglyceride levels were decreased time-dependently in both WT and CA-AhR 
mice, however, CA-AhR mice had modestly enhanced fat absorption after a peak.   
  
2.3.12 CA-AhR mice exhibited impaired glucose tolerance. 
Hepatic steatosis and heightened oxidative stress are strongly associated with impaired insulin 
signaling and hepatic insulin resistance. To determine whether activation of AhR in liver is 
involved in insulin resistance, glucose tolerance was evaluated in mice, backcrossed for 3 
generation from FVB to C57BL/6J, by intraperitoneal glucose tolerance test (GTT). Mice were 
fasted for 16hr and then challenged with i.p. injection of glucose (2g/kg). Blood samples were 
collected, and glucose levels were measured at 0, 15, 30, 60, 90, 120 180 min. As shown in 
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Figure 21, CA-AhR mice demonstrated a higher peak glucose concentration at 15 min and 
reduced clearance of plasma glucose through glucose tolerance curve, suggesting that activation 
of AhR in liver decreased glucose tolerance during GTT.          
2.4 DISCUSSION 
In this study, we have uncovered a previously unrecognized endobiotic role of AhR in hepatic 
steatosis. Our results suggest that the AhR-induced fatty liver is likely a result of the combined 
effect of increased expression of fatty acid translocase CD36/FAT, suppression of fatty acid 
oxidation, inhibition of hepatic export of triglycerides, and an increase in peripheral fat 
mobilization. We showed that CD36 is a transcriptional target of AhR and activation of AhR in 
Figure 21 CA-AhR mice exhibited impaired glucose tolerance. 
Glucose intolerance test was performed in 16hr fasted 2-month-old 
WT or CA-AhR mice. Mice were backcrossed for 3 generation 
from FVB to C57BL/6J. Blood samples were collected at indicated 
time after i.p. injection of glucose (2g/kg).   
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liver cells induced CD36 gene expression and enhanced fatty acid uptake in both mouse and 
human liver cells. 
Activation of CD36 gene expression is likely to have contributed to the steatotic effect of 
AhR, which was strongly supported by our observation that increased free fatty acid uptake by 
an AhR agonist was significantly inhibited in hepatocytes deficient of CD36. CD36 is a 
membrane fatty acid translocase capable of high affinity uptake of fatty acids. Emerging 
evidence has pointed at an important role for CD36 in controlling hepatic fatty acid uptake and 
steatosis. In patients with type 2 diabetes, food intake increases liver fatty acid uptake 
(Ravikumar et al., 2005), indicating the existence of a mechanism regulating hepatic fatty acid 
transport. An increased expression of CD36 was observed in the liver of high-fat diet fed mice 
(Inoue et al., 2005; Ito et al., 2007) and the ob/ob model of obesity and type 2 diabetes (Memon 
et al., 1999). Moreover, forced expression of CD36 in liver was sufficient to increase hepatic free 
fatty acid uptake and triglyceride storage (Koonen et al., 2007), suggesting a causative role for 
CD36 in the pathogenesis of hepatic steatosis.  
A role for CD36 in hepatic steatosis was also supported by its liver-specific regulation by 
AhR. In both the genetic and pharmacological models, the activation of AhR induced the 
expression of CD36 in liver, but not in other CD36-expressing tissues. The mechanism for the 
tissue-specific CD36 regulation remains to be determined. Nevertheless, these results strongly 
suggest CD36 has a unique role in mediating hepatic steatosis. 
The inhibition of hepatic fatty acid oxidation and VLDL-triglyceride secretion may have 
also contributed to the steatotic effect of AhR. The inhibition of fatty acid oxidation will lead to 
the storage of excess fatty acids as triglycerides. We showed that activation of AhR in transgenic 
mice inhibited peroxisomal -oxidation of fatty acids. Peroxisomal -oxidation is important 
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because peroxisomes are an exclusive site for -oxidation of very-long chain fatty acids 
(Wanders et al., 2001). Although it represents a minor pathway relative to mitochondrial -
oxidation, peroxisomal -oxidation becomes increasingly important during periods of increased 
delivery of fatty acids into the liver in pathogenic states, such as diabetes and fatty liver diseases 
(Hashimoto et al., 1999; Kroetz et al., 1998; Rao and Reddy, 2001). It is interesting that TCDD-
mediated decrease in plasma triglyceride in WT mice was not seen in the CA-AhR mice. The 
inhibition of VLDL-triglyceride secretion in TCDD-treated mice was associated with decreased 
expression and production of ApoB100 resulting in low plasma triglyceride. The correlation 
between circulating levels of triglyceride and ApoB expression has been evidenced by mouse 
models. Heterozygous ApoB knockout mice had reduced hepatic, intestinal and plasma ApoB 
expression and reduced plasma levels of triglyceride (Farese et al., 1995). In contrast, transgenic 
mice overexpressing ApoB had a higher level of circulating triglycerides (McCormick et al., 
1996).  
The decreased WAT adiposity and adipocyte hypotrophy in AhR-activated mice were 
intriguing. This effect was abrogated in CD36
-/- 
mice. The loss of fat mass might be explained by 
the activation of adipose ATGL, a predominant adipose lipase involved in fat mobilization. We 
reason the activation of ATGL gene expression may be secondary to the liver activation of AhR 
because: 1) the CA-AhR transgene was not targeted to the adipose tissue; and 2) expressing of 
CA-AhR under the fat specific aP2 gene promoter failed to activate ATGL (data not shown). It 
remains to be determined whether activation of AhR in the liver led to the production of 
hormonal factors, referred to as “hepatokines” such as FGF21, Fetuin A and retinol binding 
protein 4 (Stefan et al., 2008), which may subsequently affect extrahepatic tissues.  
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Results of this study are potentially implicated in human patients with non-alcoholic fatty 
liver disease (NAFLD), which is strongly associated with insulin resistance and metabolic 
syndrome (Kotronen and Yki-Jarvinen, 2008; Postic and Girard, 2008). If unmanaged, NAFLD 
may develop into nonalcoholic steatohepatitis (NASH), in which the fat accumulation is 
associated with inflammation (hepatitis) and scarring (fibrosis) of the liver (Green, 2003). The 
pathogenesis of NAFLD and NASH has been poorly understood. Although insulin resistance, 
influenced by genetic determinants, nutritional factors and lifestyle, plays a role in NAFLD and 
NASH, it is increasingly recognized that cytokines, including TNF and IL6, are not only 
critically involved in hepatic inflammation, liver cell death, cholestasis and fibrosis, but also 
attenuate insulin action (Tilg and Hotamisligil, 2006). At age of 5-6 weeks, CA-AhR mice 
showed increased hepatic inflammatory signaling, which are evidenced by heightened lipid 
peroxidation and oxidative stress accompanying by induction of TNF expression. While 
increase of TNF by TCDD has been reported (Umannova et al., 2007), our transgenic mouse 
model revealed the direct link between AhR pathway and inflammatory liver injury. In addition 
to increase of TNF, it remains to be determined whether AhR induces other inflammatory 
cytokines involved in NASH. Exposures to dioxin or polychlorinated biphenyls (PCBs) have 
been linked to insulin resistance and diabetes. It was reported that dioxin exposure is strongly 
associated with increased prevalence of fatty liver in human populations (Lee et al., 2006). In our 
study, we showed that treatment of human liver cells with an AhR agonist increased uptake of 
free fatty acids, providing a plausible mechanism by which polycyclic aromatic hydrocarbons, 
which can be generated during the food-cooking process, cigarette smoking, and industrial and 
military use of herbicides/pesticides, may promote fatty liver.  
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In summary, our study provides a novel and unexpected link between AhR-induced 
hepatic steatosis and the expression of fatty acid translocase CD36. The tetracycline inducible 
AhR transgenic mice, exhibiting fatty liver even when fed with a chow diet, represent a novel, 
convenient and reversible model of NAFLD. It is tempting for us to propose that AhR and its 
target CD36 may be novel therapeutic targets to manage NAFLD. It is encouraging to note that 
substantial progress has been made in the development and use of AhR antagonists (Casper et 
al., 1999; Dertinger et al., 2001; Lu et al., 1995; Puppala et al., 2008; Revel et al., 2003).  
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3.0  ANDROGEN DEPRIVATION BY LIVER X RECEPTOR-MEDIATED 
ACTIVATION OF PHASE II SULFOTRANSFERASE 
3.1 BACKGROUND 
Prostate is an androgen regulated exocrine gland of male reproductive system (Chatterjee, 2003). 
Androgens, including testosterone (T) and dihydrotestosterone 
(DHT), play an important role in the morphogenesis and 
physiology of normal prostate (Chatterjee, 2003; Denmeade 
and Isaacs, 2002; Long et al., 2005). In addition to its normal 
function, androgen is a risk factor for prostate cancer, the most 
commonly diagnosed and the second leading cause of cancer 
death in men (AmericanCancerSociety, 2006).  
The production of testosterone in the testis, where more 
than 90 % of testosterone is synthesized from cholesterol, is 
regulated by the hypothalamus-pituitary axis (Figure 22). The 
adrenal gland can also produce androgens. The hypothalamus 
stimulates the production of luteinizing hormone (LH)-
releasing hormone (LHRH), which travels into the pituitary 
gland and interacts with LHRH receptors. This interaction 
Figure 22 Androgen production 
and action. LHRH, luteinizing 
hormone (LH)-releasing hormone; 
DHT, dihydrotestosterone; AR, 
androgen receptor; ARE, AR 
responsive element 
CHAPTER  III 
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stimulates the release of LH from the pituitary gland, which subsequently binds to LH receptors 
in the testis and stimulates the production of testosterone. In target tissues, such as the prostate, 
testosterone is converted into dihydrotestosterone, which is a more potent androgen, by the 
enzyme 5-reductase. It is generally believed that most of the androgen actions are mediated by 
the androgen receptor (AR), a member of the nuclear hormone receptor superfamily (Heinlein 
and Chang, 2004; Trapman and Brinkmann, 1996). Upon activation by androgens, AR 
translocates from cytoplasm into the nucleus where it binds to the androgen responsive element 
(ARE) on target genes and recruits co-activators to facilitate gene regulation. The androgens-AR 
signaling stimulates a cascade of events that are required for prostate cancer development and 
progression. As such, the most effective endocrine therapy for prostate cancer has been androgen 
ablation. These include surgical or medical castration, as well as the use of anti-androgens 
(Denmeade and Isaacs, 2002). Upon androgen withdrawal or anti-androgen treatment, the growth 
of androgen-dependent prostate cancer cells is reduced and the cells undergo apoptosis, leading 
to tumor regression (Chatterjee, 2003).  
Other than castration and the use of anti-androgens, an important pathway to 
metabolically deactivate androgens is through the sulfotransferase-mediated sulfonation (Figure 
Figure 23 Testosterone sulfate formation and hydrolysis. SULT, sulfotransferase; 
STS, steroid sulfatase; PAP, 3‟-phosphoadenosine-5‟-phosphate; PAPS, 3‟-
phosphoadenosine-5‟-phosposulfate. 
 
 49 
23). Sulfotransferases (SULTs), a family of Phase II drug metabolizing enzymes, catalyze the 
transfer of a sulfonyl group from the co-substrate 3‟-phosphoadenosine-5‟-phosposulfate (PAPS) 
to the acceptor substrates to form sulfate or sulfamate conjugates (Glatt et al., 2001; Nagata and 
Yamazoe, 2000; Strott, 1996, 2002). Sulfonation plays an important role in steroid hormone 
deactivation, since sulfonated hormones often fail to bind to their cognate receptors and thus lose 
their hormonal activities (Raftogianis et al., 1998; Strott, 2002). Sulfoconjugation also converts 
lipophilic steroid hormones to amphiphiles, which promotes their excretion (Raftogianis et al., 
1998; Strott, 2002). The primary SULT isoform responsible for androgen sulfonation at 
physiological concentration is believed to be the hydroxysteroid sulfotransferase (SULT2A1) 
(Meloche et al., 2002; Strott, 2002). In humans, SULT2A1 is expressed in steroidogenic organs 
(adrenal and ovary), androgen-dependent tissue (prostate), tissues of the alimentary tract 
(stomach, small intestine, and colon) and liver (Strott, 2002). In rodents, Sult2a1/2a9 is 
predominantly expressed in the liver, although a lower level of its expression is also observed in 
several other tissues (Song et al., 1998).  
The potential effect of SULT2A1 on androgen metabolism has been alluded to in 
previous reports. For instance, the androgen insensitivity in the livers of pre-puberty or aged rats 
were associated with an elevated hepatic expression of Sult2a1 (Chan et al., 1998), suggesting an 
important role for Sult2a1 in androgen homeostasis. On the other hand, the expression of 
SULT2A1 has been shown to be down-regulated by androgens (Chatterjee et al., 1996; Song et 
al., 1998), which may represent a regulatory mechanism to maintain a proper androgenic 
activity. Despite the potential role of SULT2A1 in androgen metabolism, the implication of 
SULT2A1 expression and regulation in prostate regeneration and prostate cancer have not been 
systemically evaluated. In addition to SULT2A1, other androgen metabolizing enzymes have 
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also been implicated in prostate cancer. For example, increased expression of enzymes 
converting adrenal androgens to testosterone, such as the aldo-keto reductase family 1, member 
C3 (AKR1C3), was detected in androgen-independent prostate cancer, which has been proposed 
to be a potential mechanism by which prostate cancer cells adapt to androgen deprivation 
(Stanbrough et al., 2006). 
Other than SULT2A1, SULT2B1b may also contribute to androgen sulfation. It has been 
reported that recombinant SULT2B1b showed sulfonating activity toward T and DHT, although 
adrenal androgens such as androstenediol and DHEA are better substrates for this enzyme 
(Geese and Raftogianis, 2001; Strott, 2002). The steroid sulfatase (STS) also plays a role in 
androgen homeostasis. It is believed that the sulfonated androgens could be desulfonated within 
target tissues, such as the prostate, to be converted into active metabolites. Indeed, STS inhibitors 
have been explored as anti-cancer drugs for prostate cancer (Reed et al., 2005).  
LXRs have been shown to possess diverse functions, ranging from cholesterol efflux to 
lipogenesis and anti-inflammation (Zelcer et al., 2006). More recently, we showed that LXR can 
promote bile acid detoxification and alleviate cholestasis (Uppal et al., 2007). The anti-
cholestatic effect of LXR was associated with LXR-mediated activation of Sult2a1/2a9, which is 
also capable of sulfonating and detoxifying bile acids (Uppal et al., 2007). However, whether or 
not LXR plays a role in androgen homeostasis is unknown.  
In this study, we showed that activation of LXR lowered circulating androgen level in 
vivo and inhibited androgen-dependent prostate regeneration and prostate cancer cell growth. We 
also showed that sulfonated androgens failed to activate AR and expression of SULT2A1 is both 
necessary and sufficient to deactivate androgens. We propose that LXR-mediated 
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SULT2A1activation represents a novel mechanism of androgen deprivation, which may have its 
utility in developing therapies for hormone-dependent prostate cancers.  
3.2 METHODS 
Animals and prostate regeneration experiment  
The creation of FABP-VP-LXR transgenic mice has been previously described in detail (Uppal 
et al., 2007). Transgenic mice and their wild type littermates have a mixed background of 
C57BL/6J and 129/SvImJ. For the prostate regeneration experiment, mice were surgically 
castrated at 8 weeks of age. Ten days after castration, mice received daily i.p. injection of 
testosterone propionate (TP, 5 mg/kg) for 10 days to allow the prostate to regenerate (Mukai et 
al., 2005). Mice were i.p. injected with bromodeoxyuridine (BrdU, 10 mg/kg) 6 hours before 
being sacrificed. When necessary, wild type mice received TO1317 treatment (daily gavage at 50 
mg/kg) beginning 2 days before the TP treatment and continued until the completion of the 
experiment. The urogenital complex was removed and the anterior, ventral, lateral and dorsal 
prostate lobes were separated under a dissecting microscope and weighed. Ventral prostate lobes 
were processed for paraffin sections and subjected to immunostaining for BrdU or proliferating 
cell nuclear antigen (PCNA). Prostate lobes from each mouse were pooled for RNA extraction 
and gene expression analysis. Animals were sacrificed in a CO2 chamber. The use of mice in this 
study was approved by the University of Pittsburgh Institutional Animal Care and Use 
Committee.  
 
Sulfotransferase assay  
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Sulfotransferase assay using [
35
S]-PAPS (Perkin Elmer) as the sulfate donor was performed as 
previously described (Gong et al., 2007; Saini et al., 2004; Uppal et al., 2005). In brief, 20g/mL 
of total liver cytosolic extract was incubated with 5M of testosterone substrate at 37 °C. 
Reaction was terminated by the addition of ethyl acetate. Unconjugated substrate and free [
35
S]-
PAPS were extracted by vigorous mixing followed by centrifugation at 13,000 rpm for 5 min. 
The amount of radioactivity in the aqueous phase was determined by liquid scintillation. Each 
reaction was run in triplicate.   
 
Cell proliferation assay  
LNCaP and DU145 cells were maintained in RPMI-1640 medium supplemented with 10 % fetal 
bovine serum (FBS). LAPC4 cells were maintained in IMDM medium supplemented with 10 % 
FBS. Androgen independent LNCaP-derived LN05 and LAPC4-derived LA99 cells were 
maintained in phenol red-free RPMI-1640 and IMDM medium, respectively, supplemented with 
10 % charcoal/dextran-stripped FBS. Cells were seeded onto 12-well cell culture plates at the 
density of 3×10
4
/per well. After 24 hours of incubation, cells were replaced with medium 
supplemented with 10% charcoal/dextran-stripped FBS, in the absence or presence of androgens 
(testosterone or dihydrotestosterone, 10 nM each) and/or LXR ligands (22(R)-
hydroxycholesterol, GW3965, or TO1317, 10 M each). Cells were replaced with fresh medium 
daily. After 4 days of treatment, cells were trypsinized and counted with a hematocytometer. 
When necessary, cells were co-treated added 10 M of dehydroepiandrosterone (DHEA).  
 
TUNEL assay  
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LNCaP cells were seeded onto chamber slides at the density of 2.5×10
4
/per well and incubated 
overnight before treatment with various LXR agonists, including 22R-hydroxycholesterol, 
GW3965 and TO1317 (10 M each) for 3 days. Cells were then fixed with 4% 
paraformaldehyde (pH 7.4) for 30 mins. TUNEL assay were performed using an assay kit (Cat # 
11 684 795 910) from Roche Diagnostics (Indianapolis, IN). Apoptotic cells were detected by 
fluorescein staining, and the nuclei were counterstained with DAPI.   
 
Measurement of serum levels of testosterone and luteinizing hormone (LH)  
The wild type and transgenic mice were castrated at 8 weeks. Ten days after castration, mice 
received a single i.p. injection of TP (5 mg/kg) 24 hours prior to being sacrificed and serum 
testosterone levels were measured. When necessary, wild type mice received GW3965 treatment 
(daily gavage at 20 mg/kg) beginning 2 days before the TP treatment and continued until the 
completion of the experiment. Serum testosterone levels were determined using a testosterone 
enzymatic immunoassay (EIA) kit from Cayman Chemical Company (Ann Arbor, MI). 
According the manufacturer‟s specification, this EIA assay is highly specific for testosterone 
(100 %), whereas its specificity for estered testosterone and testosterone sulfate is 0.11 % and 
0.03 %, respectively. The specificity of this EIA assay to testosterone and its lack of specificity 
to testosterone propionate, testosterone sulfate, and testosterone glucuronide were experimentally 
confirmed by us (data not shown). The mouse blood samples were not extracted prior to assay. 
Non-interference was ruled out by serial dilution (data not shown). The LH levels were 
commercially measured by the University of Virginia Center for Research and Reproduction 
(www.healthsystem.virginia.edu/internet/crr/ligand.cfm).  
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Plasmid construct and transfection assay  
Expression vector for AR (pcDNA-AR) and the PSA-Luc and ARE-Luc reporter genes were 
generous gifts from Dr. Hongwu Chen (Louie et al., 2003). The human SULT2A1 cDNA was 
cloned by RT-PCR using the following pair of oligonucleotides: 5‟-
CCGGAATTCATGTCGGACGATTTCTTATGG-3‟, and 5‟- 
CTAGCTAGCTTATTCCCATGGGAACAGCTC-3‟. The SULT2A1 cDNA was digested and 
inserted into the pCMX expression vector. The identity of the cDNA was verified by DNA 
sequencing. HepG2 and DU145 cells were transfected on 48-well cell culture plates using the 
polyethyleneimine polymer transfection agent and Lipofectamine 2000, respectively. For each 
triplicate transfection of HepG2 cells, 0.8 g of reporter, 0.4 g of pcDNA-AR and 0.25 g of 
pCMX-gal were used. For DU145 cell transfection, the amounts of reporter, AR and -gal were 
0.15 g , 0.1g  and 0.25 g. Transfected cells were then treated with vehicle or androgens in 
medium containing 10% charcoal/dextran-stripped FBS for 24 hours before harvesting for 
luciferase and -gal assays. The transfection efficiency was normalized against the -gal activity.   
 
Northern blot and real-time RT-PCR analysis  
Total RNA was isolated from tissues or cell cultures using the TRIZOL reagent from Invitrogen 
(Carlsbad, CA). Northern hybridization using 
32
P-labeled cDNA probe was carried out as 
described (Barish and Evans, 2004). In the real-time RT-PCR analysis, reverse transcription was 
performed with the random hexamer primers and the Superscript RT III enzyme from Invitrogen 
following the manufacturer‟s instruction. SYBR Green-based real-time PCR was performed with 
the ABI 7300 Real-Time PCR System. Data was normalized against the control of cyclophillin 
signals. Sequences of the real-time PCR probes are shown in Appendix D. 
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LXR ribonucleic acid interference experiment  
The siRNA transfection was carried out using Lipofectamine 2000. The human LXRs and 
SULT2A1 siRNAs were added to the final concentration of 5 nM in transfection. The sequences 
of siRNAs are: LXR 5‟-AGCAGGGCUGCAAGUGGAA-3‟ (corresponding to nucleotides 
1017-1039), LXR 5‟-CAGAUCCGGAAGAAGAAGA-3‟ (corresponding to nucleotides 746-
768) SULT2A1: 5‟-CCCGAAGAACUGAACUUAA-3‟ (corresponding to nucleotides 699-721). 
All siRNAs, including the control scrambled siRNA, were ordered from QIAGEN (Valencia, 
CA). Cell were transfected for 5 hours before being replaced with medium containing 10% FBS. 
 
BrdU and PCNA immunostaining  
Tissues were fixed in 4% formaldehyde, embedded in paraffin, sectioned at 5 m, and subjected 
to immunostaining with a rat monoclonal anti-BrdU antibody (Cat# OBT0030) from Accurate 
(Westbury, NY) (1:20) or an anti-PCNA antibody (Cat # VP-P980) from Vector (Burlingame, 
CA) (1:100) using Vectastain Elite ABC Kit from Vector. Diaminobenzidine tetrahydrochloride 
(DAB) was used as the chromogen, and sections were counterstained with Gill's hematoxylin.  
3.3 RESULTS 
3.3.1 Inhibition of androgen-dependent prostate regeneration by activation of LXR  
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Uppal et al. has recently created the FABP-VP-LXRtransgenic mice that express the activated 
LXR (VP-LXR) in the liver under the control of the rat liver fatty acid binding protein  
(FABP) promoter (Uppal et al., 2007). Figure 24A shows the schematic representation of the 
transgene. Created by fusing the VP16 activation domain of the herpes simplex virus to the 
amino-terminal of mouse LXR, VP-LXR activates LXR responsive genes in a constitutive 
manner (Uppal et al., 2007). The creation of this transgenic line also led to our recent 
identification of Sult2a1/2a9 as a novel LXR target gene (Uppal et al., 2007). 
Figure 24 Genetic activation of LXR in mice inhibited androgen-dependent prostate regeneration. (A) Schematic 
representation of the FABP-VP-LXR transgenic construct. FABP promoter, fatty acid binding protein promoter. 
VP, viral protein 16. Poly A, SV40 poly(A) sequences. (B) Outline of the prostate regeneration experiment (C) 
Urogenital complex of WT and VP-LXR transgenic (VP-LXR mice. AP, anterior prostate; VP, ventral prostate; 
LP, lateral prostate; DP, dorsal prostate; BL, bladder; SV, seminal vesicle; UR, urethra. (D-F) Prostate weight (PW) 
normalized to body weight (BW) (D), prostate luminal epithelial cell proliferation was measured by BrdU 
immunostaining with the positive nuclei arrow-headed (E), and quantification of BrdU labeling index (F) in the WT 
and TG mice. In C-F, all mice, except those in C-c and C-d, were castrated at 8-weeks old, rested for 10 days, and 
then treated with testosterone propionate (TP, 5 mg/kg) for 10 days. Mice were labeled with BrdU (10 mg/kg) 6 
hours prior to being sacrificed. Mice in C-a and C-b were castrated but not TP-treated. Each group has 7-8 mice. 
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The potential effect of Sult2a1/2a9 on androgen metabolism prompted us to examine 
whether activation of LXR affects androgen homeostasis. We first evaluated the effect of LXR 
activation on androgen-dependent prostate regeneration (Figure 24B). In this experiment, wild 
type (WT) or FABP-VP-LXR transgenic (VP-LXR) mice were castrated at 8 weeks of age.  
Ten days post-castration, when the prostates have been degenerated (Figure 24C) (English et al., 
1987; Karhadkar et al., 2004), mice were treated with testosterone propionate (TP, 5 mg/kg/day, 
i.p.) for 10 days to allow the prostate to regenerate. Six hours prior to being sacrificed, mice were 
labeled with bromodeoxyuridine (BrdU, 10 mg/kg, i.p.). The urogenital complexes were 
removed, and the anterior (AP), ventral (VP), lateral (LP) and dorsal (DP) lobes of prostate were 
dissected under a dissecting microscope and weighed. As shown in Figure 24C, the prostate 
lobes in TP-treated WT mice were notably larger that their transgenic counterparts. Indeed, the 
average weights of all prostate lobes, when measured as ratios of prostate weight (PW) to body 
weight (BW), were significantly lower in the VP-LXR  mice than the WT mice (Figure 24D). It 
appeared that LXR had most profound effect on the anterior prostate. The retarded prostate 
Figure 25 Pharmacological activation of LXR in mice inhibited androgen-dependent prostate 
regeneration. (A-C) WT mice were castrated at 8-weeks old, rested for 10 days, and then treated with 
TP for 10 days, in the presence of vehicle (Veh) or TO1317 (50 mg/kg, daily gavage). The TO1317 
treatment started 2 days before the TP treatment and continued until the completion of the 
experiment. Shown are PW normalized to BW (A), prostate luminal epithelial cell proliferation was 
measured by PCNA immunostaining. (B) Quantification of PCNA-positive cells. (C) The positive 
nuclei stained with PCNA are arrow-headed.  Each group contains three mice. 
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regeneration in the VP-LXR mice was accompanied by a decrease in prostate epithelial 
proliferation as measured by BrdU immunostaining (Figure 24E). The BrdU labeling index in the 
ventral prostate of VP-LXR mice was 28% of the WT mice (Figure 24F). 
The inhibition of androgen-dependent prostate regeneration was also observed in WT 
mice treated with the LXR agonist TO1317. In this experiment, 8-week old WT male mice were 
castrated. Ten days post-castration, mice were randomly divided into two groups, with one group 
receiving daily gavage of TO1317 (50 mg/kg) and the control group receiving vehicle until the 
completion of the experiments. Our pilot experiment showed that the 50 mg/kg dose of TO1317 
is optimal to show the effect on prostate regeneration. Beginning at 12 days post-castration, all 
mice received daily i.p. injection of TP (5 mg/kg) for 10 days before being sacrificed and 
analyzed for prostate regeneration. As shown in Figure 25A, the regeneration of all lobes was 
inhibited in the TO1317-treated mice. Immunostaining of proliferating cell nuclear antigen 
(PCNA), another indicator of cell proliferation, showed that the percentage of PCNA-positive 
cells in the ventral prostate was higher in the vehicle-treated than the TO1317-treated mice 
(Figure 25B and 25C). Treatment of WT mice with GW3965, another synthetic LXR agonist, 
resulted in a similar inhibition of androgen-dependent prostate regeneration (data not shown).  
Figure 26 Activation of LXR lowered circulating level 
of active testosterone. Wild type (WT) and VP-LXR 
transgenic (VP-LXR mice were castrated at 8 weeks, 
rested for 10 days, and then treated with a single i.p. 
injection of TP (5 mg/kg) 24 hours prior to being 
sacrificed. When applicable, the GW3965 (GW) 
treatment (20 mg/kg, daily gavage) started 2 days 
before the TP treatment and continued until the 
completion of the experiment. Data represent individual 
mice. Lines represent average testosterone levels in 
each group. 
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3.3.2 Activation of LXR lowered the circulating testosterone levels  
To understand the mechanism by which LXR inhibits prostate regeneration, we measured the 
levels of testosterone in the serum of VP-LXR mice and GW3965-treated WT mice. In this 
experiment, mice were castrated at 8 weeks. Ten days after castration, mice were treated with a 
single dose of TP (5 mg/kg, i.p.) and the mice were sacrificed 24 hours after the TP injection.  
When the LXR ligand was used, the GW3965 treatment started 2 days before the TP treatment 
and continued until the completion of the experiment. As shown in Figure 26, the average serum 
testosterone concentration in TP-treated castrated WT mice was 7.4 ng/ml, similar to what has 
been reported (33). In a sharp contrast, the genetic (transgenic) or pharmacological (GW3965) 
activation of LXR resulted in significantly decreased serum concentrations of testosterone. 
Figure 27 Treatment with LXR agonists inhibited androgen-dependent LNCAP and LAPC4 prostate 
cancer cell growth. (A and B) Treatment with 10 M of LXR agonist 22(R)-hydroxycholesterol (22R), 
GW3965 (GW) and TO1317 (TO) inhibited testosterone (T, 10 nM) and dihydrotestosterone (DHT, 
10nM) induced LNCaP (A) or LAPC4 (B) cell proliferation as measured by cell number counting. Cells 
were maintained in medium supplemented with 10% charcoal/dextran-stripped FBS during the 4-day 
treatment period.  
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3.3.3 Inhibition of androgen-dependent prostate cancer cell growth by treatment with 
LXR agonists  
The inhibition of androgen-dependent prostate regeneration led us to determine whether 
activation of LXR affects androgen-dependent human prostate cancer cell growth. In this 
experiment, the AR-positive and androgen-dependent LNCaP and LAPC4 cells were treated with 
22(R)-hydroxycholesterol, GW3965 or TO1317, in the absence or presence of the supplemented 
androgens, including testosterone (T) and dihydrotestosterone (DHT) in charcoal/dextran-
stripped fetal bovine serum (FBS). As expected, treatment with T or DHT induced 2-3 fold 
increases in LNCaP cell numbers (Figure 27A). All three LXR agonists, when applied at 10 M 
concentration, inhibited the androgen dependent-LNCaP cell proliferation with TO1317 had the 
most dramatic inhibition (Figure 27A). In the absence of androgens, 22(R)-hydroxycholesterol 
and GW3965 had little effect on LNCaP cell growth, but TO1317 has a modest but significant 
inhibitory effect. GW3965 also inhibited the proliferation of LAPC4 cells, another AR-positive 
and androgen-dependent human prostate cancer cells (Figure 27B). Under the same cell culture 
condition, LXR ligands had little effect on the growth of the androgen-independent LNCaP-
Figure 28 Treatment with LXR agonists had little effect on androgen-independent prostate cancer cell growth. (A) 
LNCaP-derived LN05, (B) LAPC4-derived LA99, and (C) DU145. Cell conditions are same as Figure 27. 
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derived LN05, LAPC4-derived LA99 and DU145 cells, regardless of the androgen treatment 
(Figure 28).  
The TO1317- and GW3965-induced LNCaP growth inhibition was accompanied by a 
suppression of the mRNA expression of the prostate-specific antigen (PSA) (Figure 29A) and 
increased apoptosis as revealed by TUNEL assay (Figure 29B and 29C). Consistent with the 
result of cell proliferation, TO1317 showed the most dramatic effect in inhibiting PSA 
expression and triggering apoptosis. The inhibitory effect of LXR agonists on LNCaP cells was 
LXR dependent, since this inhibition was abolished when both LXR and LXR were knocked-
down by siRNAs (Figure 29D). The down-regulation of LXR expression in siRNA-transfected 
cells was confirmed by real-time PCR analysis (Figure 29E). 
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Figure 29 Treatment of LXR agonists decreases mRNA expression of prostate specific antigen (PSA) and 
induces apoptosis. (A-C) LNCaP cells were maintained in medium containing 10% FBS for 3 days in the 
presence of vehicle, 22R, GW or TO. Total RNA was isolated and the mRNA expression of PSA was measured 
by real-time PCR (A). Apoptosis was measured (B) and quantified (C) by TUNEL assay. UD, undetectable. 
(D) Down-regulation of LXR and LXR by siRNAs abolished the growth inhibitory effect of GW3965 on 
LNCaP cells. The treatment conditions after siRNA transfection were identical to those described in (A and B). 
The LXR ligand concentration is 10 M. The concentration for T or DHT is 10 nM. (E) The efficiencies of 
LXR knock-downs were confirmed by real-time PCR. Ctrl is lipofectamine alone control. Knockdown 
efficiency was presented as expression relative to that observed in Ctrl (arbitrarily set at 1). 
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3.3.4 Activation of LXR induced the expression of SULT2A1 and suppressed the 
expression of STS in mouse prostate and LNCaP cells  
The VP-LXR and TO1317-treated WT male mice showed markedly increased expression of 
Sult2a1/2a9 in the liver (Figure 30A), consistent with our previous report (Uppal et al., 2007). 
The liver cytosol extracts of the VP-LXR mice also exhibited a significantly higher sulfation 
activity toward testosterone, a known Sult2a1/2a9 substrate (Meloche et al., 2002; Strott, 2002) 
(Figure 30B). The basal expression of Sult2a1/2a9 in the prostate is nearly undetectable (Ct 
number was greater than 34 or the signals were “undetermined” in real-time PCR analysis), 
consistent with the notion that Sult2a1/2a9 is predominantly expressed in the liver in rodents 
(Song et al., 1998). The expressed of Sult2a1/2a9 in the prostate also failed to be induced in LXR 
ligand-treated mice (Figure 30A). Sult2b1 and Sult2b1b are expressed in the prostate, but their 
expression was not altered in response to TO1317 (Figure 30C).   
Figure 30 Activation of LXR induced the expression of SULT2a9 in the mouse liver. (A) Activation of hepatic 
Sult2a9 gene expression in VP-LXR transgenic (VP-LXR) mice and wild type (WT)-treated with TO1317 as 
shown by real-time PCR.  Each group contains 3-5 mice. UD, undetectable. (B) Increased testosterone 
sulfotransferase activity in VP-LXR mice. Cytosolic liver extracts from WT and VP-LXR  mice were incubated 
with testosterone as the substrate and [
35
S]-PAPS as the sulfate donor. Radioactivity was determined by liquid 
scintillation. (C) Expression of Sult2b1 and Sult2b1b in the prostate of WT mice mock treated or treated with 
TO1317 as shown by real-time PCR. Mice were treated with TO1317 (50 mg/kg, gavage) for 10 days. Each group 
contains three mice. 
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We have previously shown that the expression of SULT2A1 was induced in primary  
human hepatocytes treated with TO1317 (Uppal et al., 2007). Here, we showed that the 
expression of SULT2A1 was also induced in LNCaP and LAPC4 cells treated with TO1317 or 
GW3965 (Figure 31A and 31B). The human SULT2B1 was also modestly but significantly 
induced by LXR agonists, consistent with a previous report on keratinocytes (Jiang et al., 2005). 
Although recombinant SULT2B1 is capable of sulfonating T and DHT, this enzyme has been 
shown to be more effective in sulfonating adrenal androgens, such as androstenediol and DHEA 
(Geese and Raftogianis, 2001; Strott, 2002). In TO1317-treated LNCaP cells, the expression of 
Figure 31 Activation of LXR induced the expression of SULT2A1 in androgen-dependent prostate 
cancer cells and suppressed the expression of STS in the mouse liver and LNCaP cells. (A) Effect of 
TO1317 on the mRNA expression of SULT2A1 and 2B1 in LNCaP cells. Cells were treated with 
vehicle (DMSO) or 10M TO1317 for 2 days before RNA extraction and real-time PCR analysis. 
LXR and LXR are included as positive controls of LXR target genes. (B) Effect of GW3965 on the 
mRNA expression of SULT2A1 and 2B1 in LAPC4. The same conditions in (A) were used. (C) 
Knocking-down of both LXR and LXR abolished SULT2A1 activation in response to GW3965 in 
LNCaP cells as shown by real-time PCR analysis. (D) Effect of LXR ligands on the mRNA expression 
of STS in the mouse prostate and LNCaP cells as shown by real-time PCR. The same mice in Figure 
29C were used. LNCaP cells were treated with Veh (DMSO), TO1317 or GW3965 (10 M each) for 3 
days. 
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both LXR isoforms, known LXR target genes (Laffitte et al., 2001; Repa et al., 2000a; Schultz et 
al., 2000), was induced as expected (Figure 31A). The activation of SULT2A1 by GW3965 in 
LNCaP cells was LXR dependent, since knocking-down of both LXR isoforms abolished the 
SULT2A1 activation (Figure 31C).  
We also measured the effect of LXR activation on the expression of steroid sulfatase 
(STS). As shown in Figure 30D, treatment with LXR agonists inhibited the expression of STS in 
both the mouse prostate and LNCaP cells.  Interestingly, the effect of LXR on Sts expression 
appeared to be prostate-specific, since the VP-LXR transgene had little effect on the hepatic 
expression of Sts (data not shown).  
We used transient transfection and reporter gene assay to determine whether the 
sulfonated testosterone is indeed hormonally inactive. In this experiment, HepG2 cells were 
transiently transfected with AR, together with the AR-responsive natural PSA promoter reporter 
gene (PSA-LUC) or a synthetic report gene (ARE-LUC) that contains five copies of the AR 
response element (ARE) derived the PSA gene promoter. Transfected cells were then treated 
with testosterone (T), testosterone sulfate (T-Sulf), or testosterone glucuronide (T-Gluc) for 24 
hours before luciferase assay. As shown in Figure 32, treatment with T induced the reporter gene 
Figure 32 Sulfonated testosterone failed to activate AR. Sulfate conjugated-testosterone (T-Sulf) failed to 
activate AR in transient transfection and reporter gene assay. HepG2 cells were transfected with 
expression vector for AR and AR responsive PSA-LUC or ARE-LUC reporter gene as indicated. Cells 
were then treated with vehicle, testosterone (T), testosterone-sulfate (T-Sulf) or testosterone-glucuronide 
(T-Gluc) (10 nM each) for 24 hours before luciferase assay. 
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activities as expected. In a sharp contrast, the activation of both reporter genes was largely 
abolished in T-Sulf-treated cells. T-Gluc was also ineffective to activate AR (Figure 32). The 
lack of T-Sulf and T-Gluc effect may also because these two compounds cannot be internalized 
by cells. 
To determine whether activation of SULT2A1 is sufficient to deactivate androgens, 
DU145 (Figure 33A) and HepG2 (Figure 33B) cells were transfected with AR and PSA-LUC, 
together with increasing concentrations of expression vector for SULT2A1, before being treated 
with T for 24 hours. As shown in Figure 33A and 33B, co-transfection of SULT2A1 inhibited T-
induced reporter gene activation in a dose-dependent manner in both cell lines. 
To determine whether SULT2A1 activity is required for the growth inhibitory effect of 
LXR agonists, we repeated the experiment to examine the effect of TO1317 on LNCaP cell 
proliferation in the absence or presence of DHEA, a known SULT2A1-specific enzyme inhibitor 
(Lee et al., 2003; Rehse et al., 2002). As shown in Figure 34A, the inhibitory effect of TO1317 
Figure 33 Overexpression of SULT2A1 was sufficient to deactivate androgens. (A and B) Ectopic 
expression of SULT2A1 in DU145 (A) or HepG2 (B) cells was sufficient to abolish the activity of the 
exogenously added T. Cells were transfected with AR, PSA-Luc and increasing concentrations of 
SULT2A1. The SULT2A1 to AR plasmid DNA ratios are labeled. Cells were then treated with T (1 nM) 
for 24 h before luciferase assay. Inserts in A and B show the expression of the endogenous and/or 
transfected AR and SULT2A1 mRNA was confirmed by RT-PCR. Cyclophillin (Cyc) is included as a 
loading control. Lane 0 represents control CMX vector-transfected cells, and Lane 1 represents cells 
transfected with both AR and SULT2A1 at 1:1 ratio. 
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on T-stimulated cell proliferation was largely abolished, whereas DHEA treatment alone had 
little effect on the cell growth. Knocking-down the endogenous SULT2A1 in LNCaP cells was 
also efficient to abolish the growth inhibitory effect of GW3965 (Figure 34B). The efficiency of 
SULT2A1 knockdown was confirmed by real-time PCR (data not shown).   
3.3.5 Effect of LXR activation on androgen synthesis, AR expression, and pituitary 
hormone  
We have measured the expression of androgen synthesizing enzymes in the testis and prostate. 
We have previous shown that the VP- LXR transgene is expressed in the testis (Gong et al., 
2007), which was confirmed by real-time PCR (Figure 34A). Among testicular androgen 
synthesizing enzymes, the expression of 3- and 17-hydroxysteroid dehydrogenases (3-Hsd 
and 17-Hsd) was modestly but significantly increased in the transgenic mice (Figure 35A). In 
Figure 34 Activation of SULT2A1 was required for the growth inhibitory effect of LXR agonists. 
(A) The growth inhibitory effect of TO1317 on T-induced LNCaP cell proliferation was inhibited 
in the presence of the SULT2A1 inhibitor DHEA (10 M).  Proliferation was measured by cell 
countering. (B) Knocking-down of SULT2A1 by siRNA abolished the growth inhibitory effect of 
GW3965 in LNCaP cells. 
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the prostate, TO1317 treatment had no significant effect on the expression of either AR or 5-
reductase (Figure 35B). 
The synthesis of androgens is also under the influence of pituitary luteinizing hormone 
(LH). We showed that, in castrated mice that have been treated with TP for 24 hrs, neither 
GW3965 nor the transgene had significant effect on the serum level of LH (Figure 35C). In 
intact wild type male mice, treatment with GW3965 modestly but significantly induced the 
pituitary mRNA expression of Lh (Figure 35D). Both LXR and LXR are expressed in the 
pituitary, but their expression was not affected by GW3965 (Figure 35D).  
Figure 35 Effect of LXR activation on androgen synthesis, AR expression, and pituitary hormone.  (A) The VP-
LXR transgene is expressed in the testis and induced the testicular expression of 3-Hsd and 17-Hsd. Each group 
contains 4-5 mice. Insert shows the expressions of VP-LXR in the liver and testis of VP-LXR (TG) mice as 
shown by RT-PCR. Cyclophillin (Cyc) is included as a loading control. (B) Prostatic mRNA expression of androgen 
receptor (AR) and 5-reductase in WT mice treated with Veh or TO1317. Each group contains three mice. (C) 
Serum LH levels in castrated mice treated with TP for 24 h. The mice are from those described in Figure 25. (D) 
Pituitary expression of LhLXR and LXR in WT male mice treated with GW3965 for 7 days. Each group 
contains six mice. 
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3.4 DISCUSSION 
In Chapter II, we revealed a novel LXR-controlled and SULT2A1-mediated pathway of 
androgen deprivation. Genetic or pharmacological activation of LXR was sufficient to inhibit 
androgen-responsive prostate regeneration and prostate cancer cell proliferation.  
Consistent with the notion that androgens play an important role in the initiation and 
progression of prostate cancer, androgen ablation has been an effective therapy for hormone-
dependent prostate cancers. Strategies to lower testosterone level in prostate cancer patients 
include orchiectomy and the use of luteinizing hormone-releasing hormone (LHRH) agonists or 
antagonists. Orchiectomy is invasive and non-reversible. LHRH agonist therapy is widely used 
as a medical and reversible castration. Another strategy to inhibit androgenic effect is to use the 
anti-androgens. A clinical concern for the use of LHRH agonists and anti-androgens is the 
potential effect of these agents on the hypothalamic-pituitary-testicular axis after the cessation of 
the therapy. In several studies, the serum testosterone levels rose gradually upon long-term 
LHRH agonist therapy (Kinouchi et al., 2002; Morote et al., 2006). It was also reported that anti-
androgens may eventually cross the blood-brain barrier, which will promote the release of LH 
into the circulation, leading to a subsequent increase in serum testosterone level (Denmeade and 
Isaacs, 2002). Therefore, it is necessary to continue to develop novel and effective androgen 
deprivation therapies for prostate cancer with fewer side effects. Here we show that activation of 
LXR is sufficient to inhibit androgenic activity both in vivo and in cultured prostate cancer cells. 
The inhibition of prostate regeneration in LXR-activated mice was in agreement with the marked 
drop in serum testosterone levels in these animals. The activation of SULT2A1, a known LXR 
target gene, is required for the androgen deprivation effect of LXR agonists. We propose that the 
LXR-SULT2A1 pathway represents a novel mechanism of androgen deprivation.  
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The expression of SULT2A1 is known to subject to androgen regulation. It has been 
shown that activation of AR suppressed SULT2A1 expression, and the level of SULT2A1 
expression is lower in androgen- dependent prostate cancer cells (Chan et al., 1998). These 
results suggest that decreased expression of SULT2A1 may contribute to unchecked androgen 
stimulation and cancerous transformation. It is also conceivable that re-activation of SULT2A1 
may represent a novel therapeutic strategy to inhibit androgen-dependent prostate cancer growth. 
Indeed, we showed that treatment with LXR agonists inhibited androgen-dependent prostate 
cancer cell growth in LXR- and SULT2A1-dependent manner. Interestingly, SULT2A1 
regulation exhibits both tissue and species specificity. It appears that Sult2a1/2a9 activation by 
LXR in mice is liver specific. The mouse prostate has little basal or inducible expression of this 
Sult isoform, suggesting that the liver-mediated systemic androgen deprivation plays the major 
role in the prostate regeneration phenotype. In contrast, the human SULT2A1 regulation can be 
seen in both the liver and prostate cells. We have previously shown that treatment with LXR 
agonist induced the expression of SULT2A1 in primary cultures of human hepatocytes (Uppal et 
al., 2007). In the current study, we showed that LNCaP and LAPC4 cells exhibited both basal 
and inducible expression of SULT2A1 (Figure 30A and 30B).  
Interestingly, activation of LXR also decreased the expression of STS in the mouse 
prostate and LNCaP cells (Figure 31D). The prostate is a major peripheral tissue where STS 
plays an important role in producing biologically active androgens from sufonated metabolites 
(Reed et al., 2005). Our results suggest that activation of Sult2a1 in the liver and suppression of 
Sts in the prostate may function in concert to ensure the LXR-mediated androgen deprivation.  
Other than SULT2A1, other SULT isoforms, including the estrogen sulfotransferase 
(EST, or SULT1E1), are also capable of sulfonating steroid hormones. We have recently shown 
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that activation of LXR induced the expression of EST, and thus promoted estrogen deprivation. 
The expression of EST is required for the LXR effect on estrogens, since the estrogen 
deprivation phenotype was completely abolished in the EST null mice (Gong et al., 2007). EST 
is also expressed in the prostate (data not shown and ref (Takase et al., 2007)). We showed that 
GW3965 was efficient to inhibit prostate regeneration and lower the serum level of testosterone 
in the EST null mice (data not shown), suggesting that EST is not required for the androgen 
deprivation effect of LXR. Our results suggested that LXR affects androgen and estrogen 
metabolism through regulating distinct target genes. Nevertheless, the combined effect of LXR 
on androgen and estrogen metabolism suggests that LXR may function as a master regulator of 
steroid hormone homeostasis, an endocrine role distinct to the previously known sterol sensor 
role of this receptor (Tontonoz and Mangelsdorf, 2003). 
Activation of LXR has been implicated in apoptosis. Interestingly, LXR could have an 
opposite effect on apoptosis depending on the cellular context. It was reported that activation of 
LXR prevented bacterial-induced macrophage apoptosis by regulating pro-apoptotic and anti-
apoptotic regulators and effectors (Joseph et al., 2004; Valledor et al., 2004). In two other 
independent studies, LXR was found to induce -cell apoptosis through LXR-mediated 
lipotoxicity (Choe et al., 2007; Wente et al., 2007). We have recently shown that TO1317 had 
little effect on apoptosis in the MCF-7 xenograft tumors (Gong et al., 2007). Using cells 
maintained in complete serum, Fukuchi and colleagues reported that TO1317 inhibited the 
growth of both androgen-dependent and independent prostate cancer cells and this inhibition was 
associated with increased expression of the cyclin-dependent kinase inhibitor p27
Kip-1
 (Chuu et 
al., 2006; Fukuchi et al., 2004). The growth inhibitory effect of LXR agonists on androgen-
independent prostate cancer cells, such as DU145 cells, was not observed in our experiments. 
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Instead, using culture conditions of charcoal/dextran-stripped serum and the addition of 
exogenous androgens, we showed clearly that the inhibitory effect of LXR agonists on LNCaP 
cells is androgen-dependent (Figure 27). The inhibitory effect by GW3965 was LXR-dependent. 
Expression of SULT2A1 was not only induced but also required for GW3965-mediated growth 
inhibition. Other than SULT2A1, there is a possibility that this growth inhibition may be 
associated with other pathway, including G1 cell cycle arrest (Fukuchi et al., 2004). We also 
showed that treatment with GW3965 and TO1317 suppressed the expression of CDK4 protein in 
LNCaP cells, but not in DU145 cells (Appendix E), consistent with the selective growth 
inhibition.  
In vivo control of circulating androgens is subjected to the effect of the hypothalamic-
pituitary-reproductive axis. No significant changes in serum LH were detected despite significant 
reduction in circulating testosterone levels in GW3965-treated wild type and VP-LXR 
transgenic mice. It is possible that the LH secretion is not rapidly suppressed after testosterone 
treatment in castrated animals (Lindzey et al., 1998). In contrast, a significantly higher mRNA 
expression of Lh was found in the pituitary of GW3965 treated mice, consistent with a previous 
report that a combined loss of LXRs  and  in mice lowered plasma LH concentration and 
decreased the expression of androgen synthesizing enzymes (Volle et al., 2007). We can also not 
exclude the possibility that adrenal androgens may have also contributed the overall homeostasis 
of circulating androgens.   
We recognize that there are several challenges in developing LXR as a therapeutic target 
for prostate cancer. It is known that intracellular conversion of testosterone to DHT is important 
for prostatic cell proliferation. Several studies have demonstrated that a high expression of 
androgen-producing enzymes, such as the 17-Hsd and 5-reductase, is correlated with poor 
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clinical outcome of prostate cancer (Nakamura et al., 2005). It has also been reported that 
castration decreases plasma concentration of testosterone by more than 90 %, however, androgen 
levels in prostate cancer tissues decreases by only 50-60 % due to the conversion of adrenal 
androgens into DHT in prostate cancer cells (Mizokami et al., 2004). Our results showed that 
LXR activated 17-Hsd but had little effect on 5-reductase. The lipogenic effect of LXR is 
another potential concern. Androgens stimulate lipogenesis by activating lipogenic enzymes 
(Freeman and Solomon, 2004; Swinnen et al., 2006). SREBP-1c and SREBP-2, key lipogenic 
transcription factors, are up-regulated in LNCaP xenograft tumors (Hager et al., 2006), 
suggesting that aberrant regulation of lipid metabolism may play a role in prostate cancer. It 
remains to be seen whether LXR promotes lipogenesis in the prostate. It has also been reported 
that some LXR agonists could have partial or gene-specific activity to avoid the unwanted 
lipogenic side effect (Kaneko et al., 2003; Song and Liao, 2001).      
It has been reported that non-hepatic cells, including prostatic cells, can eliminate 
cholesterol by CYP27-mediated formation of 27-cholesterol and cholestenoic acid (Repa and 
Mangelsdorf, 1999). 27-hydroxycholesterol is an endogenous LXR ligand (Fu et al., 2001) and 
the expression of CYP27 decreased during the progression prostate cancer (Chuu et al., 2006). 
These results suggest that a decreased production of endogenous LXR ligands and attenuation of 
LXR signaling may contribute to the progression of prostate cancer. 
In summary, we have revealed a novel function of LXR in androgen deprivation, which 
may establish this nuclear receptor as a therapeutic target for hormone-dependent prostate 
cancer. Our results also suggest that SULT2A1 is likely the LXR target gene responsible for the 
androgen deprivation effect. We anticipate that development of LXR agonists that have more 
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specific SULT2A1 activation property may have future clinical potentials to treat hormone-
dependent prostate cancer. 
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4.0  SUMMARY AND PERSPECTIVES  
The present studies have revealed the primary contribution of AhR-mediated signaling in fatty 
acid metabolism and hepatic steatosis as summarized in Figure 36. Despite the rapidly 
accumulating evidence that exposure to dioxin results in numerous pathophysiological 
abnormalities, the transcriptional mechanisms of AhR have not been well documented, with 
exception of a few reports. In our current model, AhR can directly regulate the expression of the 
fatty acid translocase CD36. It is important to note that AhR-mediated CD36 regulation is liver-
specific, further highlighting the unique and previously unnoticed role of CD36 in hepatic 
steatosis.  
 
Figure 36 Model for AhR mediated mechanisms of hepatic steatosis 
CHAPTER  IV 
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We revealed the LXR-mediated induction of SULT2A1 can contribute to androgen 
deprivation, which is summarized in Figure 37.  LXRs have been explored as a therapeutic target 
for atherosclerosis, diabetics and Alzheimer‟s disease in animal models due to their potentials 
ranging from cholesterol efflux to lipogenesis and anti-inflammation. Our current studies have 
revealed a novel role of LXRs in regulating androgen metabolism in the liver and prostate.  
The effects of AhR and LXRs on lipid and androgen homeostasis have opened debate on 
whether these regulatory pathways can be explored as therapeutic targets to manage human 
diseases. The ligand-dependent AhR and LXR are attractive targets for drug discovery, since 
their activities can be regulated by small lipophilic molecules. Moreover, in many cases, the 
receptor agonistic and antagonistic property of small molecules can be chemically defined and 
modified. It is tempting to speculate that inhibition of AhR and selective activation of LXR to 
induce SULT2A1 may represent novel strategies to prevent or relieve fatty liver disease and 
prostate cancer, respectively.     
 
Figure 37 Model for LXR-mediated mechanisms of androgen deprivation 
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APPENDIX A 
SEQUENCES OF REAL-TIME PCR PRIMERS  
Gene Primer Sequences 
 Forward Reverse 
Cd36 
Cyp1a1 
Cyp1a2 
Fatp1 
Fatp2 
Fatp3 
Fatp4 
Fatp5 
LDLR 
VLDLR 
SR-A 
SR-B 
ApoB100 
PPAR 
Acox1 
Cyp4a10 
Cyp4a14 
L-Fabp 
CA-AhR 
cyclophillin 
CD36 
CYP1A1 
CYP3A4 
AHR 
Cyclophillin 
GGAACTGTGGGCTCATTGC 
GTGCATCGGAGAGACCATTG 
GCAGTGGAAAGACCCCTTTG 
CCGTATCCTCACGCATGTGT 
CAACACACCGCAGAAACCA 
GGAGACACCTTCAGGTGGAA 
CATGAGGAGAGTGTGGCTCA 
TCGGATCTGGGAATTCTACG 
TTCAGTGCCAATCGACTCAC 
GCGCCATGGACGAGCTG 
GACGCTTCCAGAATTTCAGC 
CACTACGCGCAGTATGTGCT 
TGTGGCAAAGGAAACAATGA 
TGTCGAATATGTGGGGACAA 
GAGCTGCTCACAGTGACTCG 
CCACAATGTGCATCAAGGAG 
TTGCCAGAATGGAGGATAGG 
AAATCGTGCATGAAGGGAAG 
CTGGGGCCATGTCCATGTATC 
TGGAGAGCACCAAGACAGACA 
AAATAAACCTCCTTGGCCTGA 
CTTCCGACACTCTTCCTTCG 
TTGCCCAGTATGGAGATGTG 
TAGTGGAGCCACAGCAACAG 
TTTCATCTGCACTGCCAAGA 
CATGAGAATGCCTCCAAACAC 
GGTAGGAGTCATATCCACCTT 
CCTTCTCGCTCTGGGTCTTG 
CTCCATCGTGTCCTCATTGAC 
ATTTCCCAGGGCTTTTTTCA 
GGCACCGTGACTCCATAGAT 
GGCTAAGGGCTTATCCCAAG 
AAGCTCAAAGGGAGTCAGCA 
TGTGACCTTGTGGAACAGGA 
TTGGCACCTGGGCTGCT 
CCAGTGAATTCCCATGTTCC 
TGAATGGCCTCCTTATCCTG 
AATCCTGCAGATTGGAGTGG 
AATCTTGCAGCTCCGATCAC 
CACGATCATCTTCCCATCCT 
TTGGGTAAAGAGCGTCCATC 
CAGGAAATTCCACTGGCTGT 
GTCTCCAGTTCGCACTCCTC 
GTCCTTGGGGTCTTCTACCTTTCTC 
TGGAGAGCACCAAGACAGACA 
GCAACAAACATCACCACACC  
GGTTGATCTGCCACTGGTTT 
AGGGGTCTTGTGGATTGTTG 
TGCTGTGGACAATTGAAAGG 
TTGCCAAACACCACATGCT 
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APPENDIX B 
MICROARRAY ANALYSIS ON THE LIVER OF CA-AHR TRANSGENIC MICE  
 
 
In livers of CA-AhR mice, 1292 genes are upregulated (A), and 1093 genes are downregulated 
(B).  Positive controls including, induction of CYP1a1, 1a2 and 1b1, are shown in (A). p<0.05 
was considered statistically significant (red rectangle). 
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B.1 PARTIAL LIST OF GENES FROM MICROARRAY ANALYSIS 
Table 1. Microarray analysis on the liver of CA-AhR transgenic mice 
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APPENDIX C 
MICROARRAY ANALYSIS OF THE INTESTINE OF CA-AHR TRANSGENIC MICE  
 
In intestines of CA-AhR mice, 2253 genes are upregulated (A), and 2203 genes are 
downregulated (B).  Positive controls, including induction of CYP1a1 and 1a2, are shown in (A). 
p<0.05 was considered statistically significant (red rectangle). 
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C.1 PARTIAL LIST OF GENES IN MICROARRAY ANALYSIS  
 
 
Table 2 Microarray analysis on the intestine of CA-AhR transgenic mice 
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APPENDIX D 
SEQUENCES OF REAL-TIME PCR PRIMERS  
Gene Primer Sequences 
 Forward Reverse 
AR (mouse) 
3-Hsd 
17-Hsd 
5-reductase 
Sult2a9 
Lxr 
Lxr 
Lh 
Sts 
Sult2b1 
Sult2b1b 
VP-LXR 
cyclophillin 
AR (human) 
LXR 
LXR 
SULT2A1 
SULT2B1 
PSA 
Cyclophillin 
CAGTGGATGGGCTGAAAAAT 
GCTTCCTGCTACGTCCAGTC 
GTTATGAGCAAGCCCTGAGC 
ACCTTTGTCTTGGCCTTCCT 
CTGGCTGTCCATGAGAGAAT 
AGGAGTGTCGACTTCGCAAA 
AAGCAGGTGCCAGGGTTCT 
ATCACCTTCACCACCAGCAT 
AGCACGAGTTCCTGTTCCAC 
TGCTGGGCAATTAAAGGACC 
CTGTGGAGCTCGTCTGAGAA 
GGCCGACTTCGAGTTTGAGC 
TGGAGAGCACCAAGACAGACA 
GAATTCCTGTGCATGAAAGCA 
CCCTTCAGAACCCACAGAGAT 
CGCTAAGCAAGTGCCTGGTT 
GGTGTATCTGGGGACTGGAA 
GGAGCTGCAGCAGGACTTAC 
CATCAGGAACAAAAGCGTGA 
TTTCATCTGCACTGCCAAGA 
CTTGAGCAGGATGTGGGATT 
CCAGATCTCGCTGAGCTTTC 
AAGCGGTTCGTGGAGAAGTA 
GGGTTACCCAGTCTTCAGCA 
GGCTTGGAAAGAGCTGTACT 
CTCTTCTTGCCGCTTCAGTTT 
TGCATTCTGTCTCGTGGTTGT 
GTAGGTGCACACTGGCTGAG 
GTTGGGCGTGAAGTAGAAGG 
AGCCCTTGATGTGGTCAAAC 
GTGAGTACATGCCGACAGGA 
GCAGAATCAGGAGAAACATC 
TGCCGGAGTCGACAATGAT 
CGAAGTTGATGAAAGAATTTTTGATT 
GCTCCTTCCCCAGCATTTT 
GCCTGGCTGTCTCTAGCAGC 
GGAACAGCTCTCGAGGAAGA 
GCGTGTAGTTGGACATGGTG 
ATATCGTAGAGCGGGTGTGG 
TTGCCAAACACCACATGCT 
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APPENDIX E 
EFFECT OF LXR ON CELL CYCLE  
 
 
LXR ligands, when applied at 10 M concentration, suppressed the expression of CDK4 in the 
androgen-dependent LNCaP cells. Cell extracts were subjected to Western blot analysis using 
indicated antibodies purchased from Santa Cruz Biotechnology INC. Cells were maintained in 
medium supplemented with 10% FBS during the 3-day treatment period.    
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